GWG Holdings, Inc. Form 424B3 November 14, 2016

Filed pursuant to Rule 424(b)(3)

Registration Nos. 333-197227 and

333-197227-01

PROSPECTUS SUPPLEMENT NO. 3	
Supplement to Prospectus dated April 12, 2016	
GWG HOLDINGS, INC.	

1,000,000 Units of L Bonds (\$1,000,000,000)

This "Prospectus Supplement No. 3 — Supplement to Prospectus dated April 12, 2016," supplements and amends our prospectus dated April 12, 2016 (referred to simply as our "prospectus"). You should read this supplement together with the prospectus since the information contained herein supplements and amends the information contained in the prospectus. This supplement supersedes and replaces prospectus supplement no. 2 dated August 12, 2016 (and, for clarity, also supersedes and replaces prospectus supplement no. 1 dated May 16, 2016). Capitalized terms contained in this supplement have the same meanings as in the prospectus unless otherwise stated herein.

RECENT EVENTS

On November 10, 2016, we filed our Quarterly Report on Form 10-Q for the period ended September 30, 2016. This prospectus supplement has been prepared primarily to set forth certain information contained in that report. This prospectus supplement also repeats certain interest-rate information originally included in prospectus supplement no. 2 dated August 12, 2016.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS SUPPLEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

This supplement is part of the prospectus and either it or its contents must accompany the prospectus to satisfy the prospectus-delivery requirements under the Securities Act of 1933.

The date of this prospectus supplement is November 10, 2016

TABLE OF CONTENTS

	Page
INTEREST RATE MATTERS	1
RISK RELATING TO FORWARD-LOOKING STATEMENTS	2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION	3
OTHER INFORMATION	31
RISK FACTOR UPDATE	32
FINANCIAL INFORMATION	F-1

GWG Holdings, Inc.

220 South Sixth Street, Suite 1200

Minneapolis, MN 55402

Tel: (612) 746-1944

Fax: (612) 746-0445

i

INTEREST RATE MATTERS

GWG Holdings, Inc. is no longer offering 6-month and 1-year L Bonds. In addition, the current offered interest rates of the L Bonds are as set forth below:

	Interest
Maturity Term	Rate (%)
2 years	5.50
3 years	6.25
5 years	7.50
7 years	8.50

On page 4 of the prospectus in the section entitled "Questions and Answers About this Offering — It seems as though you are offering several bonds with different interest rates and maturities but calling them all L Bonds. Is this the case?," the answer to the question will read:

All bonds we issue in this offering will have identical terms, excepting the interest rate and the maturity length. In this regard, we have essentially created multiple classes of L Bonds, similar to how companies may have different classes of stocks with slightly different economic rights. Currently, we are offering four classes of L Bonds, as follows:

- "Class 2-2" L Bonds will mature two years from their issuance and accrue interest at 5.50% per annum.
- "Class 3-2" L Bonds will mature three years from their issuance and accrue interest at 6.25% per annum.
- "Class 5-2" L Bonds will mature five years from their issuance and accrue interest at 7.50% per annum.
- "Class 7-2" L Bonds will mature seven years from their issuance and accrue interest at 8.50% per annum.

The economic terms for each L Bond in any particular class will be identical to all other L Bonds in the same class (other than the date of maturity). In the event we adjust the interest rate for any class of bonds we offer, we will create a new class of L Bonds. Upon the renewal of any L Bonds we have sold, any new interest rate applied to an L Bond will be applied to all L Bonds in the same class.

RISK RELATING TO FORWARD-LOOKING STATEMENTS

Certain matters discussed in this prospectus supplement contain forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions about our operations and the investments we make, including, among other things, factors discussed under the heading "Risk Factors" in the prospectus and the following:

- changes in the secondary market for life insurance;
- our limited operating history;
- the valuation of assets reflected on our financial statements;
- the reliability of assumptions underlying our actuarial models, including our life expectancy estimates;
- our reliance on debt financing;
- risks relating to the validity and enforceability of the life insurance policies we purchase;
- our reliance on information provided and obtained by third parties;
- federal, state and FINRA regulatory matters;
- competition in the secondary market of life insurance;
- the relative illiquidity of life insurance policies;
- our ability to satisfy our debt obligations if we were to sell our entire portfolio of life insurance policies;
- life insurance company credit exposure;
- general economic outlook, including prevailing interest rates;
- performance of our investments in life insurance policies;
- financing requirements;
- litigation risks;
- restrictive covenants contained in borrowing agreements;
- increases in the cost of premiums charged by insurers for the policies we own; and
- our ability to make cash distributions in satisfaction of dividend obligations and redemption requests.

Forward-looking statements can be identified by the use of words like "believes," "could," "possibly," "probably," "anticipates "estimates," "projects," "expects," "may," "will," "should," "seek," "intend," "plan," "expect," or "consider" or the negative of expressions or other variations, or by discussions of strategy that involve risks and uncertainties. All forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual transactions, results, performance or achievements to be materially different from any future transactions, results, performance or achievements expressed or implied by such forward-looking statements.

We base these forward-looking statements on current expectations and projections about future events and the information currently available to us. Although we believe that the assumptions for these forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate. Consequently, no representation or warranty can be given that the estimates, opinions, or assumptions made in or referenced by this prospectus supplement will prove to be accurate. Some of the risks, uncertainties and assumptions are identified in the discussion entitled "Risk Factors" in this prospectus supplement. We caution you that the forward-looking statements in this prospectus supplement are only estimates and predictions, or statements or current intent. Actual results or outcomes, or actions that we ultimately undertake, could differ materially from those anticipated in the forward-looking statements due to risks, uncertainties or actual events differing from the assumptions underlying these statements. These risks, uncertainties and assumptions include, but are not limited to, those discussed in this prospectus supplement.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Note: The following discussion and analysis of the financial condition and results of operations of the Company are derived from our Quarterly Report on Form 10-Q for the period ended September 30, 2016, filed with the SEC on November 10, 2016. We have not materially updated this discussion in any way, although it may be presented in a different order than in our Quarterly Report. As indicated in that report, this discussion and analysis is based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. The statements in this discussion and analysis concerning expectations regarding our future performance, liquidity and capital resources, as well as other non-historical statements in this discussion and analysis, are forward-looking statements. See "Risks Relating to Forward-Looking Statements" above and in the prospectus. These forward-looking statements are subject to numerous risks and uncertainties. Our actual results could differ materially from those suggested or implied by any forward-looking statements.

You should read the following discussion in conjunction with our condensed consolidated financial statements and related notes beginning at page F-1 of this prospectus supplement, as well as our consolidated financial statements and related notes contained within the prospectus.

Overview

GWG Holdings, Inc. is a financial services company participating in the life insurance secondary market. We create opportunities for consumers owning life insurance to obtain significant value for their contracts as compared to the traditional options offered by insurance companies. We also create opportunities for investors to participate in the life insurance alternative investment asset class, not correlated to traditional financial markets. In so doing, we enable investors to take advantage of financial opportunities dominated by banks prior to the 2008 credit crisis.

We seek to build a profitable and large portfolio of life insurance assets that are well diversified in terms of insurance companies and insureds. We believe that diversification is a key risk mitigation strategy to provide consistent cash flows and reliable investment returns from our portfolio. To grow our portfolio and achieve diversification, we offer investors the opportunity to participate in the yield potentially generated by our portfolio of life insurance assets through a variety of financings and securities offerings. We believe we are well positioned to continue providing investors with yield participation opportunities from the life insurance alternative asset class.

Critical Accounting Policies

Critical Accounting Estimates

The preparation of our consolidated financial statements in accordance with the Generally Accepted Accounting Principles (GAAP) requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our judgments, estimates, and assumptions on historical experience and on various other factors believed to be reasonable under the circumstances. Actual results could differ materially from these estimates. We evaluate our judgments, estimates, and assumptions on a regular basis and make changes accordingly. We believe that the judgments, estimates, and assumptions involved in valuing our investments in life insurance contracts have the greatest potential impact on our consolidated financial statements and accordingly believe these to be our critical accounting estimates. Below we discuss the critical accounting policies associated with these estimates as well as certain other critical accounting policies.

Ownership of Life Insurance Contracts — Fair Value Option

We account for the purchase of life insurance contracts in accordance with ASC 325-30, Investments in Insurance Contracts, which requires us to use either the investment method or the fair value method. We have elected to account for all of our life insurance contracts using the fair value method.

The fair value of our life insurance contracts is determined as the net present value of the life insurance portfolio's future expected cash flows (contract benefits received and required premium payments) that incorporates current life expectancy estimates and discount rate assumptions.

We initially record our purchase of life insurance contracts at the transaction price, which is the amount paid for the contract, inclusive of all external fees and costs associated with the acquisition. The fair value of our investment in our portfolio of insurance contracts is evaluated at the end of each subsequent reporting period. Changes in the fair value of our portfolio are based on periodic evaluations and are recorded in our consolidated and combined statement of operations as changes in fair value of life insurance contracts.

Fair Value Components — Medical Underwriting

Unobservable inputs, as discussed below, are a critical component of our estimate for the fair value of our investments in life insurance contracts. We currently use a probabilistic method of estimating and valuing the projected cash flows of our portfolio, which we believe to be the preferred and most prevalent valuation method in the industry. In this regard, the most significant assumptions we make are the life expectancy estimates of the insureds and the discount rate applied to the expected future cash flows to be derived from our portfolio.

The Society of Actuaries recently finalized the 2015 Valuation Basic Table ("2015 VBT"). The 2015 VBT is based on a much larger dataset of insured lives, face amount of contracts and more current information compared to the dataset underlying the 2008 Valuation Basic Table. The new 2015 VBT dataset includes 266 million contracts compared to the 2008 VBT dataset of 75 million. The experience data in the 2015 VBT dataset includes 2.55 million claims on contracts from 51 insurance carriers. Life expectancies implied by the 2015 VBT are generally longer for male and female nonsmokers between the ages of 65 and 80, while smokers and insureds of both genders over the age of 85 have significantly lower life expectancies. We adopted the 2015 VBT in our valuation process in June 2016.

In September 2015, Equitable Life Insurance Company ("AXA") announced pending cost-of-insurance rate increases for certain universal life contracts which were effected on March 1, 2016. We identified 14 affected contracts in our portfolio. In April 2016, we received updated contract illustrations from AXA and calculated the change in the fair value of our portfolio resulting from the increased premiums to be a reduction of \$2,395,000. This reduction was reflected in our balance sheet as of March 31, 2016. Our review of AXA's cost-of-insurance rate increases is complete as of September 30, 2016.

We are aware of additional pending cost of insurance increases affecting approximately 1.1% of our portfolio by face amount of benefits. We will adjust our premium schedules and resultant valuation when we have received the required information from the related carriers.

Fair Value Components — Required Premium Payments

We must pay the premiums on the life insurance contracts within our portfolio in order to collect the contract benefit. The same probabilistic model and methodologies used to generate expected cash inflows from the life insurance contract benefits over the expected life of the insured are used to estimate cash outflows due to required premium payments. Premiums paid are offset against revenue in the applicable reporting period.

Fair Value Components — Discount Rate

A discount rate is used to calculate the net present value of the expected cash flows. The discount rate represents the internal rate of return we expect to earn on investments in a contract or in the portfolio as a whole at the stated fair value. The discount rate used to calculate fair value of our portfolio incorporates the guidance provided by ASC 820, Fair Value Measurements and Disclosures.

The table below provides the discount rate used to estimate the fair value of our portfolio of life insurance contracts for the period ending:

September 30, 2016

December 31, 2015

11.07% 11.09%

The change in the discount rate incorporates current information about discount rates applied by other reporting companies owning portfolios of life insurance contracts, discount rates observed by us in the life insurance secondary market, market interest rates, credit exposure to the issuing insurance companies, and our estimate of the risk premium a purchaser would require to receive the future cash flows derived from our portfolio of life insurance contracts. Because we use the discount rate to arrive at the fair value of our portfolio, the rate we choose necessarily assumes an orderly and arms-length transaction (i.e., a non-distressed transaction in which neither seller nor buyer is compelled to

engage in the transaction). The carrying value of contracts acquired during each quarterly reporting period are adjusted to their current fair value using the fair value discount rate applied to the entire portfolio as of that reporting date.

We engaged Model Actuarial Pricing Systems ("MAPS"), to prepare a calculation of our life insurance portfolio. MAPS owns and maintains the portfolio pricing software we use. MAPS processed contract data, future premium data, life expectancy estimate data, and other actuarial information to calculate a net present value for our portfolio using the specified discount rate of 11.07%. MAPS independently calculated the net present value of our portfolio of 625 contracts to be \$477.6 million and furnished us with a letter documenting its calculation. A copy of such letter is filed as Exhibit 99.1 to this report.

Deferred Income Taxes

Under ASC 740, Income Taxes, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is established for deferred tax assets that are not considered more likely than not to be realized. Realization of deferred tax assets depends upon having sufficient past or future taxable income in periods to which the deductible temporary differences are expected to be recovered or within any applicable carryback or carryforward periods. After assessing the realization of the net deferred tax assets, we believe that it is "more likely than not" that we will be able to realize all of our deferred tax assets other than those which are expected to result in a capital loss.

Deferred Financing and Issuance Costs

Financing costs incurred under the senior credit facilities were capitalized and are amortized using the straight-line method over the term of the senior credit facilities. The Series I Secured Note obligations are reported net of issuance costs, sales commissions, and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The L Bonds are reported net of issuance costs, sales commissions, and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Series A, as described in Note 9, was reported net of issuance costs, sales commissions, including the fair value of warrants issued, and other direct expenses, which were amortized using the interest method as interest expense over a three-year redemption period. As of December 31, 2015, these costs have been fully amortized. Selling and issuance costs of RPS and MCA Preferred Stock, described in Notes 10 and 11, are netted against additional paid-in-capital.

Principal Revenue and Expense Items

We earn revenues from the following three primary sources.

- Life Insurance Contract Benefits Realized. We recognize the difference between the face value of the contract benefits and carrying value when an insured's mortality event occurs. We generally collect the face value of the life insurance contract benefit from the insurance company within 45 days of recognizing the revenue.
- Change in Fair Value of Life Insurance Contracts. We value our portfolio investments for each reporting period in accordance with the fair value principles discussed herein, which includes the expected payment of premiums for future periods as shown in our consolidated financial statements net premium costs.
- Sale of a Life Insurance Contract. In the event of a sale of a contract, we recognize gain or loss as the difference between the sale price and the carrying value of the contract on the date of the receipt of payment on such sale.

Our main components of expense are summarized below.

• Selling, General and Administrative Expenses. We recognize and record expenses incurred in our business operations, including operations related to the purchasing and servicing of life insurance contracts. These expenses include salaries and benefits, sales, marketing, occupancy and other expenditures.

• Interest and Dividends. We recognize and record interest expenses associated with the costs of financing our life insurance portfolio for the current period. These expenses include interest paid to our senior lender under our senior credit facilities, interest paid on our L Bonds and other outstanding indebtedness such as our Series I Secured Notes, and dividends on our Series A and our RPS. When we issue debt, we amortize the issuance costs associated with such indebtedness over the outstanding term of the financing, and classify it as interest expense.

Results of Operations — Three and Nine Months Ended September 30, 2016 Compared to the Same Periods in 2015

The following is our analysis of the results of operations for the periods indicated below. This analysis should be read in conjunction with our consolidated financial statements and related notes.

Revenue.

	 ee Months Ended tember 30,	2015		 e Months Ended tember 30,	2015		
Revenue recognized from the receipt of contract benefits Revenue (expense) recognized from the change in fair value of	\$ 4,221,000	\$	277,000	\$ 26,986,000	\$	25,909,000	
life insurance contracts, net of premiums and carrying costs(1) Gain on life insurance contracts,	9,289,000		7,912,000	24,621,000		7,538,000	
net Number of contracts matured The change in fair value related to	\$ 13,510,000 4	\$	8,189,000 1	\$ 51,607,000 16	\$	33,447,000 8	
new contracts acquired	\$ 11,668,000	\$	7,423,000	\$ 29,509,000	\$	12,546,000	

⁽¹⁾ The discount rate applied to estimate the fair value of the portfolio of life insurance contracts we own was 11.07% as of both September 30, 2016 and September 30, 2015. The carrying value of contracts acquired during each quarterly reporting period is adjusted to current fair value using the fair value discount rate applied to the entire portfolio as of that reporting date (see Note 4 to our condensed consolidated financial statements).

Expenses.

	Three Months	Ended Septem	iber 30, Increase	Nine Months Ended September 30,					
	2016	2015	(Decrease)	2016	2015	Increase			
Employee compensation and benefits ⁽¹⁾ Interest expense (including amortization of deferred financing	\$ 2,912,000	\$ 2,308,000	\$ 604,000	\$ 8,450,000	\$ 6,181,000	\$ 2,269,000			
costs and preferred stock dividends) ⁽²⁾ Legal and	11,984,000	8,650,000	3,334,000	32,010,000	23,149,000	8,861,000			
professional expenses ⁽³⁾	587,000	822,000	(235,000)	3,097,000	1,988,000	1,109,000			

Other expenses ⁽⁴⁾	2,863,00	0 2,232,000	631,000	7,608,000	5,646,000	1,962,000
Total expenses	\$ 18,346,0	00 \$ 14,012,000	0 \$ 4,334,000	\$ 51,165,000	\$ 36,964,000	\$ 14,201,000

⁽¹⁾ We hired additional members to our sales, marketing, legal and information technology teams. At the end of 2015 we employed approximately 50 employees, and at September 30, 2016 we employed approximately 67 employees.

⁽²⁾ The increase in the current period was due to the increase in our average debt outstanding.

⁽³⁾ Increase is due to SEC filings and other costs related to securities offerings and on-going compliance.

⁽⁴⁾ Increase is due to increased public relations, sales and marketing costs associated with growing and servicing our network of independent financial advisors.

Income Tax Expense.

The following table reconciles our income tax expense at the statutory federal tax rate to our actual income tax expense:

	Three Months I September 30, 2016	Ended	September 30, 2015		Nine Months September 30 2016		September 30, 2015	
Statutory federal income tax (benefit) State income taxes (benefit),	\$ (1,561,000)	34.0 %	\$ (1,948,000)	34.0 %	\$ 489,000	34.0 %	\$ 1,117,000	34.0 %
net of federal benefit Series A	(227,000)	4.9 %	(334,000)	5.8 %	240,000	16.7 %	(105,000)	3.2 %
preferred stock dividends Other	354,000	(7.7)%	175,000	(3.1)%	732,000	51.0 %	526,000	16.0 %
permanent differences Total income	15,000	(0.3)%	9,000	(0.1)%	18,000	1.3 %	31,000	1.0 %
tax expense (benefit) The most significant for	\$ (1,419,000) icant temporary of	30.9 %	\$ (2,098,000) s between GAAP	36.6 % net incor			\$ 665,000 he are the treatment	20.2 % ent of

The most significant temporary differences between GAAP net income and taxable net income are the treatment of interest costs with respect to the acquisition of the life insurance contracts and revenue recognition with respect to the fair value of life insurance portfolio.

The primary permanent difference between our effective tax rate and the statutory federal rate are the accrual of preferred stock dividend expense, state income taxes, and other non-deductible expenses. The dividends charged to interest expense were \$1.0 million and \$0.5 million during the three months ended September 30, 2016 and 2015, respectively, and \$2.2 million and \$1.5 million during the nine months ended September 30, 2016 and 2015, respectively.

Liquidity and Capital Resources

We finance our business through a combination of life insurance contract benefit receipts, origination fees, equity offerings, debt offerings, and our senior credit facilities. We have used our debt offerings and our senior credit facilities primarily for contract acquisition, contract servicing, and portfolio-related financing expenditures including paying principal and interest.

As of September 30, 2016 and December 31, 2015, we had approximately \$117.2 million and \$74.4 million, respectively, in combined available cash, cash equivalents, policy benefits receivable, if any, and available borrowing base surplus capacity, if any, under our senior credit facilities for the purpose of purchasing additional life insurance contracts, paying premiums on existing contracts, paying portfolio servicing expenses, and paying principal and interest on our outstanding financing obligations.

Debt Financings Summary

We had the following outstanding debt balances as of September 30, 2016 and December 31, 2015:

	As of September 30, 2016					As of December 31, 2015			
	Prine	cipal	Weighte	eighted Prince		cipal	Weighted		
	Amo	ount	Average	Interest	Amo	ount	Average Interes		
Issuer/Borrower	Outs	standing	Rate		Out	standing	Rate		
GWG Holdings, Inc. – L Bonds	\$	384,586,000	7.16	%	\$	282,171,000	7.18	%	
GWG Life, LLC – Series I									
Secured Notes		17,830,000	8.63	%		23,578,000	8.47	%	
Credit Facility – Autobahn									
Funding Company LLC (See									
Note 5 to our consolidated									
financial statements)		_				65,011,000	5.58	%	
Credit Facility – LNV									
Corporation (See Note 6 to our									
consolidated financial									
statements)		71,250,000	6.45	%		_	_		
Total	\$	473,666,000	7.10	%	\$	370,760,000	6.98	%	

Our total senior credit facilities and other indebtedness balance as of September 30, 2016 and December 31, 2015 was \$473.7 million and \$370.8 million, respectively. At September 30, 2016, the total outstanding face amount of our Series I Secured Notes outstanding was \$17.8 million, less unamortized selling costs of \$0.3 million, resulting in a carrying amount of \$17.5 million. At December 31, 2015, the total outstanding face amount of our Series I

Secured Notes outstanding was \$23.6 million, less unamortized selling costs of \$0.3 million, resulting in a carrying amount of \$23.3 million. At September 30, 2016, the total outstanding face amount of L Bonds was \$384.6 million plus \$6.9 million of subscriptions in process, less unamortized selling costs of \$11.6 million resulting in a carrying amount of \$379.9 million. At December 31, 2015, the total outstanding face amount of L Bonds was \$282.2 million plus \$3.0 million of subscriptions in process, less unamortized selling costs of \$8.2 million resulting in a carrying amount of \$277.0 million.

The weighted-average interest rate of our outstanding Series I Secured Notes as of September 30, 2016 and December 31, 2015 was 8.63% and 8.47%, respectively, and the weighted-average maturity at those dates was 1.31 and 1.06 years, respectively. The Series I Secured Notes have renewal features. Since we first issued our Series I Secured Notes, we experienced \$165.1 million in maturities, of which \$125.0 million renewed for an additional term as of September 30, 2016. This provided us with an aggregate renewal rate of approximately 76% for investments in these securities. Effective September 1, 2016, we no longer renew the Series I Secured Notes.

The weighted-average interest rate of our outstanding L Bonds as of September 30, 2016 and December 31, 2015 was 7.16% and 7.18%, respectively, and the weighted-average maturity at those dates was 2.10 and 2.02 years, respectively. Our L Bonds have renewal features. As of September 30, 2016, \$252.4 million in aggregate principal amount of our L Bonds had matured since issuance, of which \$168.3 million renewed for an additional term. The aggregate renewal rate is approximately 67% for investments in these securities.

Future contractual maturities of Series I Secured Notes and L Bonds at December 31, 2016 are:

	Seri	es I				
Years Ending December 31,	Secured Note		Notes L Bonds		Tota	.1
2016	\$	1,177,000	\$	23,548,000	\$	24,725,000
2017		10,522,000		112,987,000		123,509,000
2018		2,401,000		101,130,000		103,531,000
2019		1,023,000		78,098,000		79,121,000
2020		1,766,000		19,291,000		21,057,000
Thereafter		941,000		49,532,000		50,473,000
	\$	17,830,000	\$	384,586,000	\$	402,416,000

The L Bonds and Series I Secured Notes are secured by all of our assets, and are subordinate to our senior credit facilities. The L Bonds and Series I Secured Notes are pari passu with respect to a security interest in our assets pursuant to an intercreditor agreement (see Notes 7 and 8 to our consolidated financial statements).

We maintain a \$105 million revolving senior credit facility with Autobahn/DZ Bank through DLP III. The revolving senior credit facility is used to pay the premium expenses related to our portfolio of life insurance contracts. As of September 30, 2016 and December 31, 2015, we had approximately \$0 million and \$65.0 million, respectively, outstanding under the revolving senior credit facility, and maintained an available borrowing base surplus of \$76.6 million and \$40.0 million, respectively.

On September 14, 2016, we entered into a \$172 million senior secured term loan with LNV Corp. through GWG Funding DLP IV. We intend to use the proceeds from this facility primarily to grow and maintain our portfolio of life insurance contracts, for liquidity and for general corporate purposes. As of September 30, 2016 we had approximately \$71.2 million outstanding under the senior credit facility.

Capital expenditures have historically not been material and we do not anticipate making material capital expenditures in 2016 or beyond.

Corporate Financing History

In November 2009, our wholly owned subsidiary GWG Life offered Series I Secured Notes in a private placement to accredited investors only. This offering was closed in November 2011. As of September 30, 2016 and December 31, 2015, we had approximately \$17.8 million and \$23.6 million, respectively, in principal amount of Series I Secured Notes outstanding.

In September 2011, we concluded a private placement offering of Series A, having received an aggregate \$24.6 million in subscriptions for our Series A. These subscriptions consisted of \$14.0 million in conversions of outstanding Series I Secured Notes and \$10.6 million of new investments. As of September 30, 2016 and December 31, 2015, respectively, we had approximately \$19.8 million and \$20.8 million stated value of Series A outstanding.

In January 2012, we began publicly offering up to \$250.0 million in debt securities (initially named "Renewable Secured Debentures" and subsequently renamed "L Bonds") that was completed in January 2015.

In September 2014, we consummated an initial public offering of our common stock resulting in the sale of 800,000 shares of common stock at \$12.50 per share and net proceeds of approximately \$8.6 million after the deduction of underwriting commissions, discounts and expense reimbursements.

In January 2015, we began publicly offering up to \$1.0 billion of L Bonds as a follow-on offering to our earlier \$250.0 million public debt offering. Through September 30, 2016, the total amount of these L Bonds sold, including renewals, was \$637.1 million. As of September 30, 2016 and December 31, 2015, respectively, we had approximately \$384.6 million and \$282.2 million, respectively, in principal amount of L Bonds outstanding.

In October 2015, we began publicly offering up to 100,000 shares of our RPS at a per-share price of \$1,000. As of September 30, 2016 we had issued approximately \$33.2 million stated value of RPS.

Portfolio Assets and Secured Indebtedness

At September 30, 2016, the fair value of our investments in life insurance contracts of \$477.6 million plus our cash balance of \$18.8 million, our restricted cash balance of \$15.7 million and our life insurance contract benefits receivable of \$6.1 million, totaled \$518.2 million, representing an excess of portfolio assets over secured indebtedness of \$44.5 million. At December 31, 2015, the fair value of our investments in life insurance contracts of \$356.6 million plus our cash balance of \$34.4 million and our restricted cash balance of \$2.3 million, totaled \$393.3 million, representing an excess of portfolio assets over secured indebtedness of \$22.5 million. The L Bonds and Series I Secured Notes are secured by all of our assets and are subordinate to our senior credit facilities. The L Bonds and Series I Secured Notes are pari passu with respect to a security interest in our assets pursuant to an intercreditor agreement.

The following forward-looking table seeks to illustrate the impact of the sale of our portfolio of life insurance assets at various discount rates in order to satisfy our debt obligations as of September 30, 2016. In all cases, the sale of the life insurance assets owned by DLP III and DLP IV will be used first to satisfy all amounts owing under the respective senior credit facilities. The net sale proceeds remaining after satisfying all obligations under the senior credit facilities would be applied to L Bonds and Series I Secured Notes on a pari passu basis.

Portfolio Discount										
Rate	10	%	11	%	129	%	13	%	14	1%
Value of portfolio	\$	503,331,000	\$	479,200,000	\$	456,979,000	\$	436,470,000	\$	417,501,000
Cash, cash equivalents										
and life insurance										
contract benefits										
receivable		40,591,000		40,591,000		40,591,000		40,591,000		40,591,000
Total assets		543,922,000		519,791,000		497,570,000		477,061,000		458,092,000
Revolving senior										
credit facility		71,250,000		71,250,000		71,250,000		71,250,000		71,250,000
Net after revolving										
senior credit facility		472,672,000		448,541,000		426,320,000		405,811,000		386,842,000
		402,416,000		402,416,000		402,416,000		402,416,000		402,416,000

Series I Secured Notes and L Bonds Net after Series I Secured Notes and L Bonds

Bonds 70,256,000 46,125,000 23,904,000 3,395,000 (15,574,000)

Impairment to Series I

Secured Notes and L No No No No

Bonds impairment impairment impairment Impairment Impairment

The table illustrates that our ability to fully satisfy amounts owing under the L Bonds and Series I Secured Notes would likely be impaired upon the sale of all of our life insurance assets at a price equivalent to a discount rate of approximately 13.18% or higher. At December 31, 2015, the impairment occurred at a discount rate of approximately 12.58% or higher. The discount rates used to calculate the fair value of our portfolio were 11.07% and 11.09% as of September 30, 2016 and December 31, 2015, respectively.

The table does not include any allowance for transactional fees and expenses associated with a portfolio sale (which expenses and fees could be substantial), and is provided to demonstrate how various discount rates used

to value our portfolio could affect our ability to satisfy amounts owing under our debt obligations in light of our senior secured lender's right to priority payments. You should read the above table in conjunction with the information contained in other sections of this report, including our discussion of discount rates included under the "Critical Accounting Policies — Fair Value Components – Discount Rate" caption above. This discussion and analysis is based on the beliefs of our management, as well as significant assumptions made by, and information currently available to, our management.

Cash Flows

The payment of premiums and servicing costs to maintain life insurance contracts represents our most significant requirement for cash disbursement. When a contract is purchased, we are able to calculate the minimum premium payments required to maintain the contract in-force. As the insured ages, premium payments increase (see Note 3 to our consolidated financial statements). Nevertheless, the probability of actually needing to pay the premiums decreases as the probability of mortality increases. These scheduled premiums and associated probabilities are factored into our expected internal rate of return and cash-flow modeling. Beyond premiums, we incur contract servicing costs, including annual trustee, tracking costs, and debt servicing costs, including principal and interest payments, all of which are excluded from our internal rate of return calculations. Until we receive a stable amount of proceeds from the contract benefits, we intend to pay these costs from our senior credit facilities, when permitted, and through the issuance of debt securities, including the L Bonds, and equity securities including our RPS.

The amount of payments for anticipated premiums and servicing costs (excluding debt servicing costs) that we will be required to make over the next five years to maintain our current portfolio, assuming no mortalities, is set forth in the table below.

					Prer	niums and
Years Ending December 31,	Prer	niums	Serv	vicing	Serv	vicing Fees
Three months ending December 31, 2016	\$	10,449,000	\$	188,000	\$	10,637,000
2017		43,155,000		750,000		43,905,000
2018		46,847,000		750,000		47,597,000
2019		50,813,000		750,000		51,563,000
2020		56,633,000		750,000		57,383,000
2021		63,222,000		750,000		63,972,000
	\$	271,119,000	\$	3,938,000	\$	275,057,000

For the quarter-end dates set forth below, the following table illustrates the total amount of face value of contract benefits owned, and the trailing 12 months of life insurance contract benefits collected and premiums paid on our portfolio. The trailing 12-month benefits/premium coverage ratio indicates the ratio of contract benefits received to premiums paid over the trailing 12-month period from our portfolio of life insurance contracts.

		12-Month	12-Month	12-Month	
		Trailing	Trailing	Trailing	
	Portfolio Face	Benefits	Premiums	Benefits/Prem	ium
Quarter End Date	Amount	Collected	Paid	Coverage Rati	io
December 31, 2013	740,648,000	16,600,000	21,733,000	76.4	%
March 31, 2014	771,940,000	12,600,000	21,930,000	57.5	%
June 30, 2014	784,652,000	6,300,000	22,598,000	27.9	%
September 30, 2014	787,964,000	4,300,000	23,121,000	18.6	%
December 31, 2014	779,099,000	18,050,000	23,265,000	77.6	%
March 31, 2015	754,942,000	46,675,000	23,786,000	196.2	%
June 30, 2015	806,274,000	47,125,000	24,348,000	193.6	%
September 30, 2015	878,882,000	44,482,000	25,313,000	175.7	%
December 31, 2015	944,844,000	31,232,000	26,650,000	117.2	%

March 31, 2016	1,027,821,000	21,845,000	28,771,000	75.9	%
June 30, 2016	1,154,798,000	30,924,000	31,891,000	97.0	%
September 30, 2016	1,272,078,000	35,867,000	37,055,000	96.8	%
10					

We believe that the portfolio cash flow results set forth above are consistent with our general investment thesis: that the life insurance contract benefits we receive will continue to increase over time in relation to the premiums we are required to pay on the remaining polices in the portfolio. Nevertheless, we expect that our portfolio cash flow results on a period-to-period basis will remain inconsistent until such time as we achieve our goal of acquiring a larger, more diversified portfolio of life insurance contracts. As our receipt of life insurance contract benefits increases, we expect to increasingly use these cash flows to begin paying down our outstanding indebtedness and purchase additional life insurance contracts.

Inflation

Changes in inflation do not necessarily correlate with changes in interest rates. We presently do not foresee any material impact of inflation on our results of operations in the periods presented in our consolidated financial statements.

Off-Balance Sheet Arrangements

GWG Holdings is party to an office lease with U.S. Bank National Association as the landlord. Effective September 1, 2015, GWG Holdings entered into a second amendment to the lease with U.S. Bank National Association (Second Amendment to Lease). The Second Amendment to Lease increases the office space area to 17,687 square feet and extends the lease expiration date by approximately ten years (see Note 16 to our consolidated financial statements).

Credit Risk

We review the credit risk associated with our portfolio of life insurance contracts when estimating its fair value. In evaluating the contracts' credit risk, we consider insurance company solvency, credit risk indicators, economic conditions, ongoing credit evaluations, and company positions. We attempt to manage our credit risk related to life insurance contracts by generally purchasing life insurance contracts issued only from companies with an investment-grade credit rating by Standard & Poor's, Moody's, or A.M. Best Company. See "Portfolio Credit Risk Management" below.

Interest Rate Risk

Our senior credit facilities are floating-rate financing. In addition, our ability to offer interest rates that attract capital (including in our continuous offering of L Bonds) is generally impacted by prevailing interest rates. Furthermore, while our other indebtedness provides us with fixed-rate financing, our debt coverage ratio is calculated in relation to our total cost of financing. Therefore, rising interest rates could materially impact our business by increasing our borrowing costs, and reducing availability under our debt financing arrangements. Furthermore, we calculate our portfolio earnings based upon the spread generated between the return on our life insurance portfolio and the cost of our financing. As a result, increases in interest rates will reduce the earnings we expect to achieve from our investments in life insurance contracts.

Non-GAAP Financial Measures

Non-GAAP financial measures disclosed by management are provided as additional information to investors in order to provide an alternative method for assessing our financial condition and operating results. These non-GAAP financial measures are not in accordance with GAAP and may be different from non-GAAP measures used by other companies, including other companies within our industry. This presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for comparable amounts prepared in accordance with GAAP. Please see our financial statements and related notes contained herein.

We use non-GAAP financial measures for maintaining compliance with covenants contained in our borrowing agreements and for planning and forecasting purposes. The application of current GAAP standards during a period of significant growth in our business, in which period we are building a large and actuarially diverse portfolio of life insurance, results in current period operating performance that may not be reflective of our long-term earnings potential. Management believes that our non-GAAP financial measures permit investors to better focus on this long-term earnings performance without regard to the volatility in GAAP financial results that can occur during this phase of growth.

Therefore, in contrast to a GAAP fair valuation (mark-to-market), we seek to measure the accrual of the actuarial gain occurring within the portfolio of life insurance contracts at our expected internal rate of return based on statistical mortality probabilities for the insureds (using primarily the insured's age, sex, health and smoking status). The expected internal rate of return tracks actuarial gain occurring within the contracts according to a mortality table as the insureds' age increases. By comparing the actuarial gain accruing within our portfolio of life insurance contracts against our adjusted costs during the same period, we can estimate, manage and evaluate the overall financial profitability of our business without regard to mark-to-market volatility. We use this information to balance our life insurance contract purchasing and manage our capital structure, including the issuance of debt and utilization of our other sources of capital, and to monitor our compliance with borrowing covenants. We believe that these non-GAAP financial measures provide information that is useful for investors to understand period-over-period operating results separate and apart from fair value items that could have a disproportionately positive or negative impact on GAAP results in any particular period.

Our senior credit facility with Autobahn/DZ Bank requires us to maintain a "positive net income" and "tangible net worth," each of which are calculated on an adjusted non-GAAP basis using the method described above, without regard to GAAP-based fair value measures. In addition, our revolving senior credit facility with Autobahn/DZ Bank requires us to maintain an "excess spread," which is the difference between (i) the weighted average of our expected internal rate of return of our portfolio of life insurance contracts and (ii) the weighted average of our senior credit facility's interest rate. These calculations are made using non-GAAP measures in the method described below, without regard to GAAP-based fair value measures.

In addition, the Indenture governing our L Bonds and the note issuance and security agreement governing our Series I Secured Notes require us to maintain a "debt coverage ratio" designed to ensure that the expected cash flows from our portfolio of life insurance contracts is able to adequately service our total outstanding indebtedness. This ratio is calculated using non-GAAP measures in the method described below, again without regard to GAAP-based fair value measures.

Adjusted Non-GAAP Net Income. Our senior credit facility with Autobahn/DZ Bank requires us to maintain a positive net income calculated on an adjusted non-GAAP basis. We calculate the adjusted net income by recognizing the actuarial gain accruing within our life insurance contracts at the expected internal rate of return of the contracts we own without regard to fair value. We net this actuarial gain against our adjusted costs during the same period to calculate our net income on a non-GAAP basis.

	Three Months Ended September 30, 2016			115	Nine Months Ended September 30, 2016			2015		
GAAP net income (loss)	\$	(2,997,000)	\$	(3,631,000)	\$	(42,000)	\$		(2,620,000)
Unrealized fair value	_	(=,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	_	(=,===,===)	_	(,			(_,,,,,,,	,
gain(1)		(21,073,000)		(14,517,000)		(53,846,000)			(26,651,000)
Adjusted cost basis										
increase(2)		19,948,000		13,345,000		51,689,000			37,988,000	
Accrual of unrealized										
actuarial gain(3)		11,769,000		9,201,000		29,339,000			21,417,000	
Total adjusted										
non-GAAP net income(4)	\$	7,647,000	\$	4,398,000	\$	27,140,000	\$	•	30,134,000	

⁽¹⁾ Reversal of unrealized GAAP fair value gain of life insurance contracts for current period.

⁽²⁾ Adjusted cost basis is increased to include interest, premiums and servicing fees which are not capitalized under GAAP (non-GAAP cost basis).

- (3) Accrual of actuarial gain at expected internal rate of return based on the non-GAAP cost basis for the period.
- (4) We must maintain an annual positive consolidated net income, calculated on a non-GAAP basis, to maintain compliance with our revolving credit facility with Autobahn/DZ Bank.

Adjusted Non-GAAP Tangible Net Worth. Our revolving senior credit facility with Autobahn/DZ Bank requires us to maintain a tangible net worth in excess of \$45 million calculated on an adjusted non-GAAP basis. We calculate the adjusted tangible net worth by recognizing the actuarial gain accruing within our life insurance contracts at the expected internal rate of return of the contracts we own without regard to fair value. We net this actuarial gain against our adjusted costs during the same period to calculate our tangible net worth on a non-GAAP basis.

	As	of		
	September 31, 2016			of
				cember 31, 2015
GAAP net worth	\$	46,345,000	\$	16,145,000
Less intangible assets(1)		(20,320,000)		(11,562,000)
GAAP tangible net worth		26,025,000		4,583,000
Unrealized fair value gain(2)		(247,889,000)		(194,043,000)
Adjusted cost basis increase(3)		230,532,000		190,645,000
Accrual of unrealized actuarial gain(4)		140,693,000		111,355,000
Total adjusted non-GAAP tangible net worth	\$	149,361,000	\$	112,540,000

- (1) Unamortized portion of deferred financing costs and pre-paid insurance.
- (2) Reversal of cumulative unrealized GAAP fair value gain on life insurance contracts.
- (3) Adjusted cost basis is increased to include interest, premiums and servicing fees, which are not capitalized under GAAP.
- (4) Accrual of cumulative actuarial gain at expected internal rate of return based the non-GAAP cost basis.

Excess Spread. Our revolving senior credit facility with Autobahn/DZ Bank requires us to maintain a 2.00% "excess spread" between our weighted-average expected internal rate of return of our portfolio of life insurance contracts and the revolving senior credit facility's interest rate. The expected internal rate of return on the portfolio is the rate of return the portfolio would earn if all future cash flows occurred over time in proportion to the likelihood of their projected occurrence. Expected future cash flows represent the size of each potential payment (premiums and contract benefits), multiplied by the probability of that particular payment occurring. This calculation is known as the "probabilistic expectation" and it is based on actuarial estimations of life expectancy. For instance, a required premium payment of \$10,000 might be projected for a given contract at a date five years from now. If there is a 50% chance of survival for the next five years, then that particular expected cash-outflow is calculated at \$5,000. Similarly, if the contract benefit amount on the same contract is \$1 million, then during the next five years, the probable expected cash-inflow of contract benefits will total \$500,000 with the other \$500,000 projected to occur over the remaining life of the insured. The rate of return generated by the net of all such future expected cash flows for the portfolio is thus the expected IRR for the portfolio.

A presentation of our excess spread and our total excess spread is set forth below. Management uses the "total excess spread" to gauge expected profitability of our investments, and uses the "excess spread" to monitor compliance with our borrowing.

	As of	As of December 31,		
	Septembe			
	2016		2015	
Weighted-average expected IRR(1)	11.65	%	11.11	%
Weighted-average senior credit facility interest rate(2)	6.45	%	5.58	%
Excess spread	5.20	%	5.53	%

Edgar Filing: GWG Holdings, Inc. - Form 424B3

Total weighted-average interest rate on indebtedness for borrowed				
money(3)	7.10	%	6.98	%
Total excess spread(4)	4.55	%	4.13	%

⁽¹⁾ This represents the weighted-average expected internal rate of return of the life insurance contracts as of the measurement date based upon our non-GAAP cost basis of the insurance contracts and the expected cash flows from the life insurance portfolio.

	As of		As	of
	Sep	September 30, 2016		cember 31,
Investment Cost Basis	201			15
GAAP fair value	\$	477,585,000	\$	356,650,000
Unrealized fair value gain(A)		(247,889,000)		(194,043,000)
Adjusted cost basis increase(B)		230,532,000		190,645,000
Investment cost basis(C)	\$	460,228,000	\$	353,252,000

⁽A) This represents the reversal of cumulative unrealized GAAP fair value gain of life insurance contracts.

(3) Represents the weighted-average interest rate paid on all interest-bearing indebtedness as of the measurement date, determined as follows:

	As of	nber 30,	As of December 31,		
Indebtedness	2016	1001 30,	2015	1001 51,	
Senior credit facilities	\$	71,250,000	\$	65,011,000	
Series I Secured Notes	т	17,830,000	*	23,578,000	
L Bonds		384,586,000		282,171,000	
Total	\$	473,666,000	\$	370,760,000	
Interest Rates on Indebtedness					
Senior credit facilities	6.45	%	5.58	%	
Series I Secured Notes	8.63	%	8.47	%	
L Bonds	7.16	%	7.18	%	
Weighted-average interest rates paid on indebtedness	7.10	%	6.98	%	

⁽⁴⁾ Calculated as the weighted-average expected IRR (1) minus the weighted-average interest rate on interest-bearing indebtedness (3).

Debt Coverage Ratio and Subordination Ratio. Our L Bond and Series I Secured Notes borrowing covenants require us to maintain a "debt coverage ratio" of less than 90%. The "debt coverage ratio" is calculated by dividing the sum of our total interest-bearing indebtedness by the sum of our cash and cash equivalents and the net present value of the life insurance portfolio. The "subordination ratio" for our L Bonds is calculated by dividing the total interest-bearing indebtedness that is senior to L Bonds and Series I Secured Notes by the sum of the company's cash and cash equivalents and the net present value of the life insurance portfolio. The "subordination ratio" must be less than 50%. For purposes of both ratio calculations, the net present value of the life insurance portfolio is calculated using a discount rate equal to the weighted average interest rate paid on all indebtedness. As of the date of this report, the subordination ratio provisions under the Indenture have expired.

As of	As of
September 30,	December 31,

⁽B) Adjusted cost basis is increased to include interest, premiums and servicing fees which are not capitalized under GAAP.

⁽C) This is the non-GAAP cost basis in life insurance contracts from which our expected internal rate of return is calculated.

⁽²⁾ This is the weighted-average interest rate for both senior credit facilities as of the measurement date.

	201	.6		201	.5	
Life insurance portfolio contract benefits	\$	1,272,078,000)	\$	944,844,000)
Discount rate of future cash flows		7.10	%		6.98	%
Net present value of Life insurance portfolio contract benefits	\$	586,332,000		\$	435,738,000)
Cash and cash equivalents		34,462,000			36,767,000	
Life insurance contract benefits receivable		6,129,000				
Total Coverage		626,923,000			472,505,000)
Senior credit facilities		71,250,000			65,011,000	
Series I Secured Notes		17,830,000			23,578,000	
L Bonds		384,586,000			282,171,000)
Total Indebtedness	\$ 473,666,000			\$	370,760,000)
Debt Coverage Ratio		75.55	%		78.47	%
Subordination Ratio		11.36	%		13.76	%
17						

As of September 30, 2016, we were in compliance with both the debt coverage ratio and the subordination ratio.

Non-GAAP Expected Portfolio Internal Rate of Return at Purchase. The non-GAAP expected portfolio internal rate of return (IRR) at purchase is calculated as the weighted average (by face amount of contract benefits) of the IRR expected at the time of purchase for all life insurance contracts in the portfolio. This non-GAAP measure isolates our IRR expectation at purchase and utilizes our underwriting life expectancy assumptions at the time. This measure does not change with the passage of time as compared to our non-GAAP cost basis that increases with the payment of premiums, financing costs, and the effective life expectancy which changes over time, both of which are used to calculate our expected portfolio IRR.

	As of September 30, 2016			As of December 31, 2015		
Life insurance portfolio contract benefits Total number of polices		1,272,078, 625	000	\$	944,844,00 396	00
Non-GAAP Expected Portfolio Internal Rate of Return at Purchase		15.70	%		15.71	%

We have in the past reported non-GAAP net asset value among our other non-GAAP financial measures. We have determined, however, to cease reporting this measure primarily because we do not believe that it is sufficiently additive to our existing non-GAAP measures in aiding users of our financial statements and disclosures to measure and evaluate our financial condition or operating results. Moreover, we are not aware of other reporting companies in our industry that use this measure to evaluate their financial condition or operating results.

Portfolio Information

Our portfolio of life insurance contracts, owned by our subsidiaries as of September 30, 2016, is summarized below:

Life Insurance Portfolio Summary

1,272,078,000	
2,035,000	
2,263,000	
81.8	
6.8	
625	
562	
73% Males; 27%	
Females	
24	
0.79	%
0.16	%
3.33	%
	6.8 625 562 73% Males; 27% Females 24 0.79 0.16

^{*} Averages presented in the table are weighted averages.

Our portfolio of life insurance contracts, owned by our wholly owned subsidiaries as of September 30, 2016, organized by the insured's current age and the associated number of contracts and contract benefits, is summarized below:

Distribution of Contracts and Contract Benefits by Current Age of Insured

					Wtd. Avg.				
					Life	Percenta	age of Tot	al	
			Con	ıtract	Expectancy	Number	of	Contract	
Min Age	Max Age	Contracts	Ben	efits	(yrs.)	Contrac	ts	Benefits	
90	96	55	\$	105,815,000	2.4	8.8	%	8.3	%
85	89	155	\$	331,989,000	4.8	24.8	%	26.1	%
80	84	152	\$	385,904,000	6.7	24.3	%	30.3	%
75	79	115	\$	251,466,000	9.2	18.4	%	19.8	%
70	74	87	\$	120,791,000	9.8	13.9	%	9.5	%
65	69	61	\$	76,113,000	10.1	9.8	%	6.0	%
Total		625	\$	1,272,078,000	6.8	100.0	%	100.0	%

Our portfolio of life insurance contracts, owned by our wholly owned subsidiaries as of September 30, 2016, organized by the insured's estimated life expectancy estimates and associated contract benefits, is summarized below:

Distribution of Contracts by Current Life Expectancies of Insured

					Percenta	ige of Tot	al	
Min LE	Max LE				Number	of	Contract	-
(Months)	(Months)	Contracts	Con	tract Benefits	Contract	ts	Benefits	
6	47	160	\$	275,036,000	25.6	%	21.6	%
48	71	145		300,501,000	23.2	%	23.6	%
72	95	112		249,118,000	17.9	%	19.6	%
96	119	97		223,012,000	15.5	%	17.6	%
120	143	63		134,822,000	10.1	%	10.6	%
144	202	48		89,589,000	7.7	%	7.0	%
Total		625	\$	1,272,078,000	100.0	%	100.0	%

We track concentrations of pre-existing medical conditions among insured individuals within our portfolio based on information contained in life expectancy reports. We track these medical conditions within the following ten primary disease categories: (1) cancer, (2) cardiovascular, (3) cerebrovascular, (4) dementia, (5) diabetes, (6) multiple, (7) neurological disorders, (8) no disease, (9) other, and (10) respiratory diseases. Our primary disease categories are summary generalizations based on the ICD-9 codes we track on each insured individuals within our portfolio. ICD-9 codes, published by the World Health Organization, are used worldwide for medical diagnoses and treatment systems, as well as morbidity and mortality statistics. Currently, the only primary disease category within our portfolio that represents a concentration of over 10% is cardiovascular, which constitutes 21.25% of the value of our portfolio.

Portfolio Credit Risk Management

We rely on the payment of life insurance contract benefit claims by life insurance companies as our most significant source of cash flow. The life insurance assets we own represent obligations of third-party life insurance companies to pay face value of the life insurance contract benefits. As a result, we manage this credit risk exposure by generally purchasing contracts issued by insurance companies with investment-grade ratings from Standard & Poor's, and diversifying our portfolio among a number of insurance companies.

As of September 30, 2016, 97.0% of our life insurance contracts, by face value benefits, were issued by insurance companies that maintained an investment-grade rating (BBB- or better) by Standard & Poor's. Our largest life insurance company credit exposures and their respective Standard & Poor's credit rating of their respective financial strength and claims paying ability is set forth below:

			Percentage	of		
			Contract			
			Benefit			Ins. Co. S&P
Rank	Cont	ract Benefits	Amount		Insurance Company	Rating
1	\$	182,494,000	14.3	%	AXA Equitable Life Insurance Company	A+
					John Hancock Life Insurance Company	
2	\$	165,255,000	13.0	%	(U.S.A.)	AA-
3	\$	145,721,000	11.5	%	Lincoln National Life Insurance Company	AA-
4	\$	129,116,000	10.1	%	Transamerica Life Insurance Company	AA-
5	\$	89,806,000	7.1	%	Metropolitan Life Insurance Company	A+
					Massachusetts Mutual Life Insurance	
6	\$	57,250,000	4.5	%	Company	AA+
7	\$	50,975,000	4.0	%	American General Life Insurance Company	A+
8	\$	48,095,000	3.8	%	Pacific Life Insurance Company	A+
9	\$	45,300,000	3.6	%	Reliastar Life Insurance Company	A
10	\$	44,990,000	3.5	%	West Coast Life Insurance Company	AA-
		959,002,000	75.4	%		

The yield to maturity on bonds issued by life insurance carriers reflects, among other things, the credit risk (risk of default) of such insurance carrier. We track the yields on certain publicly traded life insurance company bonds as this information is part of the data we consider when valuing our portfolio of life insurance contracts for our financial statements according to GAAP. Also we believe that these yields provide investors a market-based perspective on the financial strength of the largest life insurance companies backing our portfolio.

				Duration	Bond S&P
Name of Bond	Maturity	YTM		(Years)	Rating
AXA 7.125%	12/15/2020	1.54	%	4.2	BBB
Manulife Finl 4.15%	3/4/2026	2.83	%	9.4	A
Lincoln National Corp Ind 3.35%	3/9/2025	3.05	%	8.7	A-
Amer Intl Grp 4.875%	6/1/2022	2.48	%	5.7	A-
Protective Life 7.375%	10/15/2019	2.18	%	3.0	A-
Metro Life Gbl Fd1 4.75%	9/17/2021	3.01	%	5.0	AA-
Prudential Finl Inc Mtns Book 4.5%	5/15/2024	2.97	%	7.9	A
Average yield on insurance bonds		2.58	%	6.3	

The table above indicates the current yields to maturity (YTM) for the senior bonds of selected life insurance carriers with durations, on average, that are similar to our life insurance portfolio. The average yield to maturity of these bonds was 3.02%, which, we believe, reflects in part the financial market's judgement that credit risk is low with regard to these carriers' financial obligations. It should be noted that the obligations of life insurance carriers to pay life insurance contract benefits is senior in rank to any other obligation. This "super senior" priority is not reflected in the yield to maturity in the table and, if considered, would result in a lower yield to maturity all else being equal. As such, as long as the respective premium payments have been made, it is highly likely that the owner of the life insurance contract will collect the insurance contract benefit upon the mortality of the insured.

The complete detail of our portfolio of life insurance contracts, owned by our wholly owned subsidiaries as of September 30, 2016, organized by the current age of the insured and the associated contract benefits, sex, estimated life expectancy, issuing insurance carrier, and the credit rating of the issuing insurance carrier, is set forth below.

Life Insurance Portfolio Detail (as of September 30, 2016)

	Face	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
1	\$	1,100,000	Male	96	17	Reliastar Life Insurance Company	A
2	\$	184,000	Male	95	38	Reliastar Life Insurance Company	A
3	\$	219,000	Male	95	38	Reliastar Life Insurance Company	A
4	\$	8,000,000	Female	95	14	Massachusetts Mutual Life Insurance Company	AA+
5	\$	4,000,000	Male	95	25	Metropolitan Life Insurance Company	A+
6	\$	1,500,000	Female	95	24	Accordia Life and Annuity Company	A-
7	\$	3,200,000	Male	95	15	West Coast Life Insurance Company	AA-
8	\$	1,000,000	Female	94	22	Transamerica Life Insurance Company	AA-
						North American Company for Life and Health	
9	\$	250,000	Male	94	23	Insurance	A+
10	\$	264,000	Female	94	11	Lincoln Benefit Life Company	BBB+
11	\$	125,000	Female	94	6	Lincoln National Life Insurance Company	AA-
12	\$	3,500,000	Male	93	29	Reliastar Life Insurance Company	A
						John Hancock Life Insurance Company	
13	\$	500,000	Male	93	7	(U.S.A.)	AA-
14	\$	2,000,000	Female	93	7	Pruco Life Insurance Company	AA-
15	\$	500,000	Female	93	41	Sun Life Assurance Company of Canada (U.S.)	AA-
16	\$	250,000	Male	93	7	Transamerica Life Insurance Company	AA-
17	\$	1,682,773	Female	92	40	Hartford Life and Annuity Insurance Company	BBB+
18	\$	572,429	Female	92	26	Reliastar Life Insurance Company	A
19	\$	3,000,000	Male	92	31	West Coast Life Insurance Company	AA-
						John Hancock Life Insurance Company	
20	\$	500,000	Female	92	55	(U.S.A.)	AA-
21	\$	5,000,000	Female	92	43	American General Life Insurance Company	A+
22	\$	400,000	Female	92	59	Principal Life Insurance Company	A+
						John Hancock Life Insurance Company	
23	\$	5,000,000	Female	92	23	(U.S.A.)	AA-
24	\$	1,000,000	Female	92	26	Lincoln National Life Insurance Company	AA-
25	\$	300,000	Female	92	17	West Coast Life Insurance Company	AA-
26	\$	3,845,000	Female	92	36	Pacific Life Insurance Company	A+
27	\$	500,000	Male	91	40	Massachusetts Mutual Life Insurance Company	AA+
						John Hancock Life Insurance Company	
28	\$	5,000,000	Male	91	23	(U.S.A.)	AA-
29	\$	500,000	Female	91	15	Lincoln National Life Insurance Company	AA-
			_			John Hancock Life Insurance Company	
30	\$	3,500,000	Female	91	62	(U.S.A.)	AA-
31	\$	3,100,000	Female	91	25	Lincoln Benefit Life Company	BBB+
32	\$	1,500,000	Female	91	54	Lincoln National Life Insurance Company	AA-
33	\$	3,000,000	Female	91	25	Lincoln National Life Insurance Company	AA-
34	\$	5,000,000	Female	91	31	Reliastar Life Insurance Company	A
35	\$	5,000,000	Female	91	12	Lincoln National Life Insurance Company	AA-
36	\$	500,000	Male	91	41	Reliastar Life Insurance Company	A

					Voya Retirement Insurance and Annuity	
37	\$ 1,000,000	Male	91	7	Company	A
38	\$ 1,203,520	Male	91	33	Columbus Life Insurance Company	AA
39	\$ 1,350,000	Female	91	27	Lincoln National Life Insurance Company	AA-
40	\$ 600,000	Female	91	15	Columbus Life Insurance Company	AA
41	\$ 5,000,000	Female	90	38	Massachusetts Mutual Life Insurance Company	AA+
42	\$ 2,500,000	Female	90	38	American General Life Insurance Company	A+
43	\$ 2,500,000	Male	90	45	Pacific Life Insurance Company	A+
44	\$ 1,000,000	Female	90	40	United of Omaha Life Insurance Company	AA-
18						

	Fac	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
45	\$	375,000	Male	90	33	Lincoln National Life Insurance Company	AA-
46	\$	1,103,922	Female	90	51	Sun Life Assurance Company of Canada (U.S.)	AA-
47	\$	1,000,000	Female	90	54	Transamerica Life Insurance Company	AA-
48	\$	250,000	Female	90	54	Transamerica Life Insurance Company	AA-
49	\$	500,000	Female	90	34	Transamerica Life Insurance Company	AA-
50	\$	2,500,000	Female	90	4	AXA Equitable Life Insurance Company	A+
51	\$	2,500,000	Female	90	4	AXA Equitable Life Insurance Company Nationwide Life and Annuity Insurance	A+
52	\$	500,000	Female	90	27	Company	A+
53	\$	715,000	Female	90	45	Lincoln National Life Insurance Company	AA-
54	\$	2,225,000	Female	90	74	Transamerica Life Insurance Company	AA-
55	\$	3,500,000	Female	90	32	Lincoln National Life Insurance Company	AA-
56	\$	1,000,000	Female	89	45	Metropolitan Life Insurance Company	A+
57	\$	248,859	Female	89	25	Lincoln National Life Insurance Company	AA-
58	\$	500,000	Female	89	57	Sun Life Assurance Company of Canada (U.S.)	AA-
59	\$	250,000	Male	89	60	Metropolitan Life Insurance Company	A+
60	\$	4,000,000	Female	89	61	Transamerica Life Insurance Company	AA-
61	\$	5,000,000	Male	89	42	AXA Equitable Life Insurance Company	A+
62	\$	1,200,000	Male	89	42	Massachusetts Mutual Life Insurance Company	AA+
63	\$	1,200,000	Male	89	42	Massachusetts Mutual Life Insurance Company	AA+
		, ,				John Hancock Life Insurance Company	
64	\$	1,050,000	Male	89	34	(U.S.A.)	AA-
65	\$	3,000,000	Male	89	85	Transamerica Life Insurance Company	AA-
66	\$	1,000,000	Male	89	44	AXA Equitable Life Insurance Company	A+
67	\$	500,000	Male	89	52	Lincoln National Life Insurance Company	AA-
	·	,				John Hancock Life Insurance Company	
68	\$	4,785,380	Female	89	32	(U.S.A.)	AA-
69	\$	1,803,455	Female	89	55	Metropolitan Life Insurance Company	A+
70	\$	1,529,270	Female	89	55	Metropolitan Life Insurance Company	A+
71	\$	800,000	Male	89	54	Lincoln National Life Insurance Company	AA-
						John Hancock Life Insurance Company	
72	\$	5,000,000	Male	89	41	(U.S.A.)	AA-
73	\$	500,000	Female	89	41	Transamerica Life Insurance Company	AA-
74	\$	400,000	Female	89	41	Lincoln Benefit Life Company	BBB+
75	\$	3,000,000	Female	89	70	Massachusetts Mutual Life Insurance Company	AA+
76	\$	200,000	Male	89	40	Lincoln Benefit Life Company	BBB+
77	\$	4,445,467	Male	89	47	Penn Mutual Life Insurance Company	A+
78	\$	1,500,000	Male	89	35	Union Central Life Insurance Company	A+
79	\$	7,500,000	Male	89	39	Lincoln National Life Insurance Company	AA-
80	\$	3,600,000	Female	89	54	AXA Equitable Life Insurance Company	A+
81	\$	3,000,000	Male	89	33	Lincoln National Life Insurance Company	AA-
						John Hancock Life Insurance Company	
82	\$	2,000,000	Male	89	36	(U.S.A.)	AA-
83	\$	100,000	Female	89	46	American General Life Insurance Company	A+
84	\$	100,000	Female	89	46	American General Life Insurance Company	A+
85	\$	396,791	Male	89	26	Lincoln National Life Insurance Company	AA-
86	\$	1,500,000	Male	89	93	Transamerica Life Insurance Company	AA-
						John Hancock Life Insurance Company	
87	\$	1,000,000	Male	88	45	(U.S.A.)	AA-

					John Hancock Life Insurance Company	
88	\$ 2,000,000	Male	88	45	(U.S.A.)	AA-
89	\$ 5,000,000	Male	88	41	Lincoln National Life Insurance Company	AA-
90	\$ 5,000,000	Female	88	27	Transamerica Life Insurance Company	AA-
91	\$ 3,000,000	Male	88	36	Transamerica Life Insurance Company	AA-
92	\$ 1,200,000	Male	88	62	Transamerica Life Insurance Company	AA-
93	\$ 6,000,000	Female	88	46	Sun Life Assurance Company of Canada (U.S.)	AA-
19						

	Fac	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
94	\$	250,000	Male	88	40	Wilton Reassurance Life Insurance Company	N/A
95	\$	330,000	Male	88	60	AXA Equitable Life Insurance Company	A+
96	\$	175,000	Male	88	60	Metropolitan Life Insurance Company	A+
97	\$	335,000	Male	88	60	Metropolitan Life Insurance Company	A+
98	\$	3,000,000	Male	88	65	AXA Equitable Life Insurance Company	A+
99	\$	2,000,000	Female	88	40	Beneficial Life Insurance Company	N/A
						John Hancock Life Insurance Company	
100	\$	250,000	Female	88	40	(U.S.A.)	AA-
101	\$	1,000,000	Female	88	30	New York Life Insurance Company	AA+
102	\$	1,250,000	Male	88	27	Columbus Life Insurance Company	AA
103	\$	300,000	Male	88	27	Columbus Life Insurance Company	AA
104	\$	10,000,000	Female	88	61	West Coast Life Insurance Company	AA-
105	\$	2,500,000	Male	88	37	Transamerica Life Insurance Company	AA-
106	\$	8,500,000	Male	88	68	Massachusetts Mutual Life Insurance Company	AA+
107	\$	1,000,000	Female	88	41	West Coast Life Insurance Company	AA-
108	\$	2,000,000	Female	88	41	West Coast Life Insurance Company	AA-
109	\$	500,000	Female	88	45	Beneficial Life Insurance Company	N/A
110	\$	800,000	Male	88	44	National Western Life Insurance Company	A
111	\$	1,269,017	Male	88	25	Hartford Life and Annuity Insurance Company	BBB+
112	\$	5,000,000	Male	88	68	Lincoln National Life Insurance Company	AA-
113	\$	4,513,823	Female	88	18	Accordia Life and Annuity Company	A-
113	\$	2,000,000	Male	88	78	Security Life of Denver Insurance Company	A
115	Ф \$	2,000,000	Male	88	78 78	Security Life of Denver Insurance Company	A
116	\$ \$	2,000,000	Male	88	78 78	Security Life of Denver Insurance Company	A
117	\$ \$	309,000	Male	88	27	Transamerica Life Insurance Company	AA-
117	\$ \$	2,000,000	Female	88	64	U.S. Financial Life Insurance Company	AA- A+
119	\$ \$		Female	87	82	- ·	AA-
	\$ \$	1,365,000				Transamerica Life Insurance Company	AA- A
120 121	\$ \$	1,000,000	Female	87 87	76 75	Security Life of Denver Insurance Company	A AA-
121	\$ \$	200,000	Female	87 87	73 38	Lincoln National Life Insurance Company	
123	\$ \$	1,000,000	Male	87 87	36 29	Sun Life Assurance Company of Canada (U.S.)	AA-
	Ф	1,000,000	Male			Massachusetts Mutual Life Insurance Company	AA+
124	\$	1,000,000	Female	87	19	State Farm Life Insurance Company	AA-
125	\$	2,000,000	Male	87	85	Transamerica Life Insurance Company	AA-
126	\$	209,176	Male	87	81	Lincoln National Life Insurance Company	AA-
127	\$	2,328,547	Male	87	34	Metropolitan Life Insurance Company	A+
128	\$	2,000,000	Male	87	34	Metropolitan Life Insurance Company	A+
129	\$	1,000,000	Male	87	23	Transamerica Life Insurance Company	AA-
130	\$	500,000	Male	87	69	Metropolitan Life Insurance Company	A+
131	\$	750,000	Female	87	71	Lincoln National Life Insurance Company	AA-
132	\$	1,500,000	Female	87	71	Lincoln National Life Insurance Company	AA-
133	\$	400,000	Female	87	71	Lincoln National Life Insurance Company	AA-
134	\$	1,250,000	Female	87	71	Lincoln National Life Insurance Company	AA-
135	\$	2,000,000	Male	87	50	Lincoln National Life Insurance Company	AA-
136	\$	3,000,000	Female	87	54	Transamerica Life Insurance Company	AA-
137	\$	347,211	Male	87	30	Pruco Life Insurance Company	AA-
						John Hancock Life Insurance Company	
138	\$	1,800,000	Male	87	41	(U.S.A.)	AA-
139	\$	2,000,000	Male	87	51	AXA Equitable Life Insurance Company	A+
140	\$	1,750,000	Male	87	51	AXA Equitable Life Insurance Company	A+

141	\$ 4,000,000	Male	87	41	Metropolitan Life Insurance Company	A+
142	\$ 2,000,000	Male	87	25	Transamerica Life Insurance Company	AA-
20						

	Face			Age	LE		S&P
	Amo	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
			Male	87	63	John Hancock Life Insurance Company	C
143	\$	1,425,000				(U.S.A.)	AA-
144	\$	1,500,000	Male	87	48	AXA Equitable Life Insurance Company	A+
145	\$	1,500,000	Male	86	27	Transamerica Life Insurance Company	AA-
146	\$	1,500,000	Female	86	96	Lincoln Benefit Life Company	BBB+
147	\$	3,750,000	Male	86	63	AXA Equitable Life Insurance Company	A+
148	\$	2,000,000	Male	86	43	Metropolitan Life Insurance Company	A+
149	\$	3,000,000	Male	86	43	Metropolitan Life Insurance Company	A+
			Male	86	29	John Hancock Life Insurance Company	
150	\$	1,000,000				(U.S.A.)	AA-
151	\$	2,000,000	Female	86	73	AXA Equitable Life Insurance Company	A+
152	\$	1,000,000	Male	86	43	Security Life of Denver Insurance Company	A
153	\$	3,000,000	Female	86	71	Sun Life Assurance Company of Canada (U.S.)	AA-
154	\$	125,000	Male	86	53	Jackson National Life Insurance Company	AA
155	\$	1,500,000	Male	86	66	AXA Equitable Life Insurance Company	A+
156	\$	1,000,000	Male	86	45	AXA Equitable Life Insurance Company	A+
157	\$	5,000,000	Male	86	75	Security Life of Denver Insurance Company	A
158	\$	1,500,000	Male	86	38	Reliastar Life Insurance Company	A
159	\$	1,500,000	Male	86	38	Reliastar Life Insurance Company	A
160	\$	5,000,000	Male	86	60	Security Life of Denver Insurance Company	A
161	\$	500,000	Male	86	31	Genworth Life Insurance Company	BB
162	\$	1,980,000	Male	86	40	New York Life Insurance Company	AA+
	·	, ,	Male	86	36	John Hancock Life Insurance Company	
163	\$	1,000,000				(U.S.A.)	AA-
164	\$	500,000	Male	86	39	New England Life Insurance Company	AA-
165	\$	4,000,000	Female	86	41	Reliastar Life Insurance Company	A
166	\$	284,924	Male	86	51	Transamerica Life Insurance Company	AA-
167	\$	5,000,000	Female	86	80	American General Life Insurance Company	A+
168	\$	500,000	Female	86	25	Transamerica Life Insurance Company	AA-
169	\$	3,500,000	Female	86	95	Lincoln Benefit Life Company	BBB+
170	\$	800,000	Male	86	40	Metropolitan Life Insurance Company	A+
171	\$	5,000,000	Female	85	88	AXA Equitable Life Insurance Company	A+
	·	-,,	Female	85	71	John Hancock Life Insurance Company	
172	\$	1,000,000				(U.S.A.)	AA-
173	\$	6,000,000	Female	85	98	American General Life Insurance Company	A+
174	\$	5,000,000	Male	85	53	AXA Equitable Life Insurance Company	A+
	·	-,,	Male	85	44	Security Mutual Life Insurance Company of	
175	\$	1,433,572				NY	N/A
176	\$	2,000,000	Male	85	42	National Life Insurance Company	A
177	\$	1,000,000	Female	85	34	Metropolitan Life Insurance Company	A+
	·	, ,	Female	85	107	John Hancock Life Insurance Company	
178	\$	2,147,816				(U.S.A.)	AA-
179	\$	4,200,000	Female	85	105	Transamerica Life Insurance Company	AA-
180	\$	750,000	Male	85	75	West Coast Life Insurance Company	AA-
	ŕ	,	Male	85	26	John Hancock Life Insurance Company	*
181	\$	4,000,000			-	(U.S.A.)	AA-
		,	Male	85	65	John Hancock Life Insurance Company	
182	\$	1,000,000				(U.S.A.)	AA-
183	\$	2,000,000	Female	85	86	Lincoln Benefit Life Company	BBB+
100	4	_,000,000	1 1111110		00		,

184	\$ 2,000,000	Female	85	62	New York Life Insurance Company	AA+
185	\$ 5,000,000	Male	85	62	Lincoln National Life Insurance Company	AA-
186	\$ 2,400,000	Male	85	27	Genworth Life Insurance Company	BB
187	\$ 3,000,000	Male	85	80	Transamerica Life Insurance Company	AA-
		Male	85	93	John Hancock Life Insurance Company	
188	\$ 8,500,000				(U.S.A.)	AA-
189	\$ 600,000	Male	85	88	AXA Equitable Life Insurance Company	A+
190	\$ 7,600,000	Female	85	85	Transamerica Life Insurance Company	AA-
191	\$ 250,000	Male	85	18	Midland National Life Insurance Company	A+
2.1						

	Fac	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
192	\$	250,000	Male	85	41	Transamerica Life Insurance Company	AA-
193	\$	2,500,000	Female	85	58	American General Life Insurance Company	A+
194	\$	2,500,000	Male	85	47	AXA Equitable Life Insurance Company	A+
195	\$	3,000,000	Male	85	47	Lincoln National Life Insurance Company	AA-
196	\$	2,000,000	Male	85	73	Pacific Life Insurance Company	A+
197	\$	7,600,000	Male	85	89	Transamerica Life Insurance Company	AA-
198	\$	3,000,000	Female	85	36	AXA Equitable Life Insurance Company Voya Retirement Insurance and Annuity	A+
199	\$	250,000	Male	85	68	Company	A
200	\$	1,800,000	Female	85	50	Lincoln National Life Insurance Company	AA-
201	\$	1,703,959	Male	85	58	Lincoln National Life Insurance Company	AA-
202	\$	3,000,000	Male	85	49	Metropolitan Life Insurance Company	A+
203	\$	500,000	Male	85	11	Great Southern Life Insurance Company	N/A
204	\$	2,247,450	Female	85	49	Transamerica Life Insurance Company	AA-
205	\$	1,000,000	Male	85	46	Hartford Life and Annuity Insurance Company	BBB+
206	\$	400,000	Male	85	39	Transamerica Life Insurance Company	AA-
207	\$	1,000,000	Male	85	81	Lincoln National Life Insurance Company	AA-
208	\$	1,000,000	Male	85	51	Metropolitan Life Insurance Company	A+
209	\$	3,500,000	Male	85	54	Pacific Life Insurance Company	A+
210	\$	2,500,000	Male	85	54	AXA Equitable Life Insurance Company	A+
211	\$	10,000,000	Male	84	116	Pacific Life Insurance Company	A+
212	\$	87,677	Female	84	47	Protective Life Insurance Company	AA-
213	\$	1,000,000	Male	84	51	Texas Life Insurance Company	N/A
214	\$	500,000	Male	84	92	Metropolitan Life Insurance Company	A+
215	\$	1,000,000	Male	84	57	Lincoln National Life Insurance Company	AA-
216	\$ \$	3,000,000	Male	84	30	U.S. Financial Life Insurance Company	AA- A+
210	Ψ	3,000,000	Maic	04	30	Genworth Life and Annuity Insurance	Αт
217	\$	325,000	Male	84	53	•	ВВ
217	Ф	323,000	Maie	04	33	Company Converte Life and Amerity Incomes	DD
210	\$	175 000	Male	84	53	Genworth Life and Annuity Insurance	BB
218 219		175,000	Male	84 84	33 48	Company	
	\$	850,000				American General Life Insurance Company	A+
220	5	600,000	Male	84	61	Massachusetts Mutual Life Insurance Company	AA+
221	\$	1,900,000	Male	84	54	American National Insurance Company	A
222	\$	500,000	Male	84	35	New York Life Insurance Company	AA+
223	\$	500,000	Male	84	35	New York Life Insurance Company	AA+
224	\$	5,000,000	Male	84	46	AXA Equitable Life Insurance Company	A+
225	\$	385,000	Male	84	62	Metropolitan Life Insurance Company	A+
226	\$	500,000	Male	84	62	Metropolitan Life Insurance Company	A+
227	\$	75,000	Male	84	39	Fidelity and Guaranty Insurance Company	BBB-
228	\$	10,000,000	Male	84	62	Lincoln National Life Insurance Company	AA-
229	\$	1,500,000	Male	84	67	Lincoln National Life Insurance Company	AA-
230	\$	250,000	Male	84	41	The Ohio State Life Insurance Company	N/A
231	\$	3,500,000	Female	84	77	AXA Equitable Life Insurance Company	A+
232	\$	1,000,000	Female	84	89	West Coast Life Insurance Company	AA-
233	\$	1,000,000	Female	84	66	American General Life Insurance Company	A+
234	\$	5,000,000	Female	84	65	Sun Life Assurance Company of Canada (U.S.)	AA-
235	\$	3,000,000	Female	84	57	Metropolitan Life Insurance Company John Hancock Life Insurance Company	A+
236	\$	750,000	Male	84	67	(U.S.A.)	AA-

237	\$ 4,500,000	Male	84	61	AXA Equitable Life Insurance Company	A+
238	\$ 1,250,000	Female	84	51	Columbus Life Insurance Company	AA
239	\$ 2,275,000	Male	84	80	Reliastar Life Insurance Company	A
240	\$ 10,000,000	Male	84	72	AXA Equitable Life Insurance Company	A+
22						

	Face	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
241	\$	340,000	Female	84	75	Jackson National Life Insurance Company	AA
242	\$	2,300,000	Male	84	13	American General Life Insurance Company	A+
243	\$	3,500,000	Male	84	60	AXA Equitable Life Insurance Company	A+
244	\$	6,217,200	Female	84	94	Phoenix Life Insurance Company	B+
245	\$	2,500,000	Female	84	62	Reliastar Life Insurance Company	A
246	\$	5,000,000	Female	84	48	Massachusetts Mutual Life Insurance Company	AA+
247	\$	1,275,000	Male	84	44	General American Life Insurance Company	A+
248	\$	2,000,000	Female	84	86	Lincoln National Life Insurance Company	AA-
249	\$	1,000,000	Male	84	41	American General Life Insurance Company	A+
250	\$	750,000	Male	84	78	AXA Equitable Life Insurance Company	A+
251	\$	5,000,000	Male	84	71	Lincoln National Life Insurance Company	AA-
252	\$	3,000,000	Male	83	56	Protective Life Insurance Company	AA-
253	\$	1,500,000	Male	83	56	American General Life Insurance Company	A+
254	\$	2,000,000	Female	83	94	Transamerica Life Insurance Company	AA-
255	\$	1,500,000	Male	83	61	Pacific Life Insurance Company	A+
256	\$	2,000,000	Male	83	75	New York Life Insurance Company	AA+
257	\$	5,000,000	Male	83	97	American General Life Insurance Company	A+
258	\$	250,000	Male	83	132	Reliastar Life Insurance Company	A
259	\$	1,995,000	Female	83	69	Transamerica Life Insurance Company	AA-
260	\$	4,000,000	Male	83	46	Lincoln National Life Insurance Company	AA-
261	\$	10,000,000	Male	83	69	New York Life Insurance Company	AA+
262	\$	1,000,000	Male	83	59	Hartford Life and Annuity Insurance Company	BBB+
263	\$	1,000,000	Male	83	59	Jackson National Life Insurance Company	AA
264	\$	417,300	Male	83	90	Jackson National Life Insurance Company	AA
265	\$	5,000,000	Male	83	68	Transamerica Life Insurance Company	AA-
266	\$	2,000,000	Male	83	59	Ohio National Life Assurance Corporation	AA-
267	\$	1,000,000	Male	83	59	Ohio National Life Assurance Corporation	AA-
268	\$	500,000	Female	83	92	AXA Equitable Life Insurance Company	A+
269	\$	350,000	Male	83	26	Jackson National Life Insurance Company	AA
						Security Mutual Life Insurance Company of	
270	\$	5,000,000	Female	82	68	NY	N/A
271	\$	5,000,000	Male	82	80	AXA Equitable Life Insurance Company	A+
272	\$	6,000,000	Male	82	96	Transamerica Life Insurance Company	AA-
273	\$	8,000,000	Male	82	73	AXA Equitable Life Insurance Company	A+
274	\$	850,000	Female	82	89	Zurich Life Insurance Company	AA-
275	\$	550,000	Male	82	106	Genworth Life Insurance Company	BB
276	\$	500,000	Male	82	54	West Coast Life Insurance Company	AA-
277	\$	1,680,000	Female	82	59	AXA Equitable Life Insurance Company	A+
278	\$	1,000,000	Female	82	86	Lincoln National Life Insurance Company	AA-
279	\$	1,250,000	Male	82	89	Metropolitan Life Insurance Company	A+
280	\$	3,000,000	Female	82	61	AXA Equitable Life Insurance Company	A+
281	\$	1,000,000	Male	82	55	AXA Equitable Life Insurance Company	A+
282	\$	1,250,000	Female	82	75	Principal Life Insurance Company	A+
283	\$	1,000,000	Male	82	47	AXA Equitable Life Insurance Company	A+
284	\$	1,500,000	Male	82	60	Lincoln Benefit Life Company	BBB+
285	\$	700,000	Male	82	91	Banner Life Insurance Company	AA-
						John Hancock Life Insurance Company	
286	\$	3,000,000	Male	82	88	(U.S.A.)	AA-
287	\$	10,000,000	Male	82	60	Hartford Life and Annuity Insurance Company	BBB+

288	\$ 1,750,000	Male	82	72	AXA Equitable Life Insurance Company	A+
289	\$ 5,000,000	Male	82	62	AXA Equitable Life Insurance Company	A+
23						

	Face	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
290	\$	300,000	Female	82	64	Hartford Life and Annuity Insurance Company	BBB+
291	\$	250,000	Male	82	70	American General Life Insurance Company	A+
292	\$	3,500,000	Male	82	76	Metropolitan Life Insurance Company	A+
293	\$	2,502,000	Male	82	136	Transamerica Life Insurance Company	AA-
						John Hancock Life Insurance Company	
294	\$	10,000,000	Male	82	102	(U.S.A.)	AA-
295	\$	250,000	Female	82	93	Accordia Life and Annuity Company	A-
296	\$	3,000,000	Male	82	115	Principal Life Insurance Company	A+
297	\$	1,700,000	Male	82	54	Lincoln National Life Insurance Company	AA-
298	\$	1,210,000	Male	82	56	Lincoln National Life Insurance Company	AA-
299	\$	3,000,000	Female	82	96	West Coast Life Insurance Company	AA-
300	\$	7,000,000	Male	82	76	Genworth Life Insurance Company	BB
301	\$	8,000,000	Male	81	118	Metropolitan Life Insurance Company	A+
302	\$	3,000,000	Male	81	81	Reliastar Life Insurance Company	A
303	\$	4,000,000	Male	81	72	Lincoln National Life Insurance Company	AA-
	4	.,000,000	1.1010	01	. –	Genworth Life and Annuity Insurance	
304	\$	500,000	Male	81	46	Company	BB
305	\$	3,000,000	Male	81	136	Metropolitan Life Insurance Company	A+
306	\$	300,000	Female	81	90	Metropolitan Life Insurance Company	A+
307	\$	200,000	Male	81	64	Protective Life Insurance Company	AA-
308	\$	150,000	Male	81	64	Protective Life Insurance Company	AA-
309	\$	150,000	Male	81	64	Protective Life Insurance Company	AA-
310	\$	350,000	Male	81	64	Lincoln National Life Insurance Company	AA-
311	\$	1,187,327	Male	81	88	Transamerica Life Insurance Company	AA-
311	Ψ	1,107,327	Maic	01	00	John Hancock Life Insurance Company	ΑΛ-
312	\$	5,000,000	Male	81	99	(U.S.A.)	AA-
312	Ψ	3,000,000	Iviaic	01	77	North American Company for Life And Health	AA-
313	\$	800,000	Male	81	70	Insurance	A+
314	\$	2,000,000	Male	81	20	Metropolitan Life Insurance Company	A+
315	\$ \$	1,000,000	Female	81	80	Lincoln Benefit Life Company	BBB+
316	\$ \$	6,000,000	Male	81	113	AXA Equitable Life Insurance Company	A+
310	Ψ	0,000,000	Iviaic	01	113	John Hancock Life Insurance Company	АТ
317	\$	320,987	Female	81	96	(U.S.A.)	AA-
317	\$ \$	130,000	Male	81	43	Genworth Life Insurance Company	BB
319	\$ \$	5,500,000	Male	81	113	Metropolitan Life Insurance Company	вв А+
320	\$ \$	1,000,000	Male	81	113	Protective Life Insurance Company	AA-
						_ ·	
321	\$ \$	2,000,000	Female	81	80 87	Pacific Life Insurance Company Lincoln National Life Insurance Company	A+
322		4,000,000	Male	81		Lincoln National Life Insurance Company	AA-
323	\$	2,000,000	Male	81	74	Metropolitan Life Insurance Company	A+
324	\$	2,000,000	Male	81	74	Metropolitan Life Insurance Company	A+
325	\$	4,300,000	Female	81	101	American National Insurance Company	A
326	\$	200,000	Male	81	59	Kansas City Life Insurance Company	N/A
327	\$	2,000,000	Female	81	67	Transamerica Life Insurance Company	AA-
328	\$	1,500,000	Female	81	68	Protective Life Insurance Company	AA-
329	\$	1,000,000	Male	81	49	Pacific Life Insurance Company	A+
330	\$	200,000	Male	81	40	Pruco Life Insurance Company	AA-
331	\$	500,000	Male	81	40	Transamerica Life Insurance Company	AA-
332	\$	3,000,000	Male	80	35	Pacific Life Insurance Company	A+
333	\$	3,000,000	Male	80	35	Minnesota Life Insurance Company	A+

334	\$	3,000,000	Male	80	35	Pruco Life Insurance Company	AA-
JJ+	Ψ	3,000,000	Iviaic	80	33	Truco Life insurance Company	ΔΔ-
335	\$	5,000,000	Male	80	89	Pacific Life Insurance Company	A+
336	\$	5,000,000	Male	80	89	Pacific Life Insurance Company	A+
337	\$	3,601,500	Male	80	85	Transamerica Life Insurance Company	AA-
338	\$	1,000,000	Male	80	87	Sun Life Assurance Company of Canada (U.S.)	AA-
24							

	Face			Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
						John Hancock Life Insurance Company	
339	\$	5,000,000	Male	80	80	(U.S.A.)	AA-
340	\$	5,000,000	Male	80	120	Principal Life Insurance Company	A+
341	\$	150,000	Male	80	85	MetLife Insurance Company USA	A+
						John Hancock Life Insurance Company	
342	\$	1,009,467	Male	80	51	(U.S.A.)	AA-
343	\$	7,000,000	Male	80	77	Lincoln Benefit Life Company	BBB+
						North American Company for Life And Health	
344	\$	100,000	Male	80	57	Insurance	A+
345	\$	1,000,000	Male	80	108	Lincoln National Life Insurance Company	AA-
						John Hancock Life Insurance Company	
346	\$	5,000,000	Male	80	49	(U.S.A.)	AA-
347	\$	6,799,139	Male	80	114	AXA Equitable Life Insurance Company	A+
348	\$	476,574	Male	80	64	Transamerica Life Insurance Company	AA-
349	\$	2,250,000	Male	80	85	Massachusetts Mutual Life Insurance Company	AA+
350	\$	775,000	Male	80	115	Lincoln National Life Insurance Company	AA-
						John Hancock Life Insurance Company	
351	\$	1,000,000	Female	80	115	(U.S.A.)	AA-
352	\$	6,000,000	Male	80	111	AXA Equitable Life Insurance Company	A+
353	\$	1,445,000	Female	80	97	AXA Equitable Life Insurance Company	A+
354	\$	1,500,000	Female	80	97	AXA Equitable Life Insurance Company	A+
355	\$	1,000,000	Male	80	78	Lincoln National Life Insurance Company	AA-
356	\$	200,000	Male	80	50	Lincoln National Life Insurance Company	AA-
357	\$	1,000,000	Male	80	102	Metropolitan Life Insurance Company	A+
358	\$	6,000,000	Male	80	98	AXA Equitable Life Insurance Company	A+
359	\$	5,000,000	Female	80	108	Reliastar Life Insurance Company	A
360	\$	750,000	Male	80	61	Lincoln National Life Insurance Company	AA-
361	\$	5,000,000	Male	80	170	West Coast Life Insurance Company	AA-
362	\$	3,000,000	Male	80	87	Principal Life Insurance Company	A+
363	\$	5,000,000	Male	79	129	Lincoln National Life Insurance Company	AA-
364	\$	3,000,000	Male	79	78	American General Life Insurance Company	A+
						John Hancock Life Insurance Company	
365	\$	5,000,000	Male	79	71	(U.S.A.)	AA-
						John Hancock Life Insurance Company	
366	\$	500,000	Male	79	60	(U.S.A.)	AA-
367	\$	1,000,000	Male	79	106	Metropolitan Life Insurance Company	A+
368	\$	1,250,000	Male	79	91	AXA Equitable Life Insurance Company	A+
369	\$	3,000,000	Female	79	81	New York Life Insurance Company	AA+
370	\$	4,000,000	Male	79	43	Metropolitan Life Insurance Company	A+
371	\$	2,500,000	Male	79	79	Massachusetts Mutual Life Insurance Company	AA+
372	\$	2,500,000	Male	79	79	Massachusetts Mutual Life Insurance Company	AA+
373	\$	500,000	Female	79	108	Columbus Life Insurance Company	AA
374	\$	4,000,000	Female	79	86	Transamerica Life Insurance Company	AA-
						John Hancock Life Insurance Company	
375	\$	4,000,000	Male	79 	140	(U.S.A.)	AA-
376	\$	325,000	Male	79	36	American General Life Insurance Company	A+
						John Hancock Life Insurance Company	
377	\$	1,750,000	Male	79 7 9	56	(U.S.A.)	AA-
378	\$	5,000,000	Male	79	96	Transamerica Life Insurance Company	AA-

379	\$ 3,750,000	Male	79	52	AXA Equitable Life Insurance Company	A+
380	\$ 550,000	Male	79	72	Pruco Life Insurance Company	AA-
381	\$ 300,000	Male	79	72	Pruco Life Insurance Company	AA-
382	\$ 2,000,000	Female	79	50	Transamerica Life Insurance Company	AA-
383	\$ 1,200,000	Female	78	126	Athene Annuity & Life Assurance Company	A-
384	\$ 1,000,000	Male	78	98	Accordia Life and Annuity Company	A-
385	\$ 2,840,000	Male	78	91	Transamerica Life Insurance Company	AA-
					North American Company for Life and Health	
386	\$ 750,000	Male	78	82	Insurance	A+
					John Hancock Life Insurance Company	
387	\$ 1,000,000	Male	78	82	(U.S.A.)	AA-
25						

	Fac	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
						North American Company for Life and Health	
388	\$	500,000	Male	78	82	Insurance	A+
389	\$	50,000	Male	78	40	Lincoln National Life Insurance Company	AA-
390	\$	4,000,000	Male	78	62	Massachusetts Mutual Life Insurance Company	AA+
						John Hancock Life Insurance Company	
391	\$	1,000,000	Female	78	68	(U.S.A.)	AA-
						John Hancock Life Insurance Company	
392	\$	1,000,000	Female	78	123	(U.S.A.)	AA-
393	\$	2,000,000	Male	78	94	Lincoln National Life Insurance Company	AA-
394	\$	2,000,000	Male	78	94	Lincoln National Life Insurance Company	AA-
395	\$	5,000,000	Male	78	113	Lincoln National Life Insurance Company	AA-
396	\$	1,000,000	Male	78	115	Principal Life Insurance Company	A+
397	\$	2,000,000	Male	78	100	Genworth Life Insurance Company	BB
						John Hancock Life Insurance Company	
398	\$	6,250,000	Male	78	185	(U.S.A.)	AA-
399	\$	490,620	Male	78	80	Ameritas Life Insurance Corporation	A+
400	\$	600,000	Male	78	77	Protective Life Insurance Company	AA-
		•				John Hancock Life Insurance Company	
401	\$	400,000	Male	78	113	(U.S.A.)	AA-
402	\$	730,000	Male	77	96	Transamerica Life Insurance Company	AA-
403	\$	5,000,000	Male	77	142	Pruco Life Insurance Company	AA-
404	\$	300,000	Male	77	73	Penn Mutual Life Insurance Company	A+
405	\$	5,000,000	Male	77	131	AXA Equitable Life Insurance Company	A+
406	\$	3,000,000	Male	77	91	Pruco Life Insurance Company	AA-
						John Hancock Life Insurance Company	
407	\$	3,000,000	Female	77	101	(U.S.A.)	AA-
408	\$	5,000,000	Male	77	136	Massachusetts Mutual Life Insurance Company	AA+
409	\$	5,000,000	Male	77	136	Massachusetts Mutual Life Insurance Company	AA+
410	\$	200,000	Female	77	139	West Coast Life Insurance Company	AA-
411	\$	1,100,000	Male	77	133	Accordia Life and Annuity Company	A-
412	\$	3,000,000	Male	77	97	Protective Life Insurance Company	AA-
413	\$	2,000,000	Female	77	113	Accordia Life and Annuity Company	A-
414	\$	10,000,000	Male	77	127	AXA Equitable Life Insurance Company	A+
						John Hancock Life Insurance Company	
415	\$	2,500,000	Male	77	134	(U.S.A.)	AA-
						John Hancock Life Insurance Company	
416	\$	2,500,000	Male	77	134	(U.S.A.)	AA-
		, ,				Athene Annuity & Life Assurance Company of	
417	\$	1,000,000	Male	77	98	New York	A-
418	\$	7,000,000	Female	77	116	Pacific Life Insurance Company	A+
419	\$	100,946	Female	77	154	Genworth Life and Annuity Insurance Company	BB
420	\$	350,000	Male	77	106	AXA Equitable Life Insurance Company	A+
421	\$	600,000	Male	77	106	AXA Equitable Life Insurance Company	A+
422	\$	1,000,000	Male	77	77	Pacific Life Insurance Company	A+
423	\$	2,000,000	Male	77	113	Transamerica Life Insurance Company	AA-
424	\$	200,000	Male	77	111	Prudential Insurance Company of America	AA-
425	\$	2,000,000	Female	77	162	Lincoln National Life Insurance Company	AA-
426	\$	150,000	Male	77	99	Genworth Life Insurance Company	BB
427	\$	2,000,000	Male	77	58	Athene Annuity & Life Assurance Company	A-
		· •				· · ·	

428	\$ 7,097,434	Male	77	153	Lincoln National Life Insurance Company	AA-
429	\$ 5,000,000	Male	77	54	West Coast Life Insurance Company	AA-
430	\$ 1,000,000	Male	76	122	Transamerica Life Insurance Company	AA-
431	\$ 750,000	Male	76	107	Protective Life Insurance Company	AA-
432	\$ 250,000	Male	76	98	Midland National Life Insurance Company	A+
433	\$ 3,000,000	Male	76	51	Accordia Life and Annuity Company	A-
434	\$ 200,000	Male	76	65	Reliastar Life Insurance Company	A
435	\$ 500,000	Male	76	96	AXA Equitable Life Insurance Company	A+
					John Hancock Life Insurance Company	
436	\$ 3,000,000	Male	76	108	(U.S.A.)	AA-
26						

	Fac	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
						John Hancock Life Insurance Company	
437	\$	5,000,000	Male	76	108	(U.S.A.)	AA-
438	\$	8,000,000	Male	76	94	Metropolitan Life Insurance Company	A+
439	\$	100,000	Male	76	53	AXA Equitable Life Insurance Company	A+
440	\$	4,000,000	Female	76	137	American General Life Insurance Company	A+
441	\$	500,000	Male	76	88	AIG Life Insurance Company	A+
						Security Mutual Life Insurance Company of	
442	\$	1,000,000	Male	76	155	NY	N/A
443	\$	355,700	Male	76	103	Security Life of Denver Insurance Company	A
444	\$	5,000,000	Male	76	54	Lincoln Benefit Life Company	BBB+
445	\$	250,000	Male	76	135	West Coast Life Insurance Company	AA-
446	\$	1,000,000	Male	76	112	Transamerica Life Insurance Company	AA-
						John Hancock Life Insurance Company	
447	\$	2,000,000	Male	76	146	(U.S.A.)	AA-
448	\$	7,500,000	Female	76	173	Security Life of Denver Insurance Company	Α
449	\$	3,000,000	Female	76	110	General American Life Insurance Company	A+
450	\$	100,000	Male	76	67	Transamerica Life Insurance Company	AA-
451	\$	300,000	Female	76	133	Minnesota Life Insurance Company	A+
452	\$	250,000	Male	76	88	United of Omaha Life Insurance Company	AA-
453	\$	600,000	Male	75	69	United of Omaha Life Insurance Company	AA-
454	\$	500,000	Male	75	87	Protective Life Insurance Company	AA-
455	\$	1,000,000	Male	75	93	Security Life of Denver Insurance Company	Α
456	\$	1,000,000	Male	75	96	Transamerica Life Insurance Company	AA-
457	\$	500,000	Male	75	89	AXA Equitable Life Insurance Company	A+
458	\$	500,000	Male	75	103	United of Omaha Life Insurance Company	AA-
						North American Company for Life And Health	
459	\$	750,000	Male	75	27	Insurance	A+
460	\$	8,000,000	Female	75	131	West Coast Life Insurance Company	AA-
461	\$	250,000	Female	75	155	AXA Equitable Life Insurance Company	A+
462	\$	300,000	Male	75	36	Lincoln National Life Insurance Company	AA-
463	\$	172,245	Female	75	54	Symetra Life Insurance Company	A
464	\$	5,004,704	Male	75	133	American General Life Insurance Company	A+
465	\$	2,000,000	Male	75	119	Pruco Life Insurance Company	AA-
466	\$	190,000	Male	75	103	Protective Life Insurance Company	AA-
467	\$	100,000	Male	75	151	Protective Life Insurance Company	AA-
468	\$	5,000,000	Male	75	129	AIG Life Insurance Company	A+
						Security Mutual Life Insurance Company of	
469	\$	4,000,000	Male	75	108	NY	N/A
470	\$	89,626	Female	75	117	Union Central Life Insurance Company	A+
471	\$	2,000,000	Male	75	94	American General Life Insurance Company	A+
472	\$	10,000,000	Female	75	134	Reliastar Life Insurance Company	A
						John Hancock Life Insurance Company	
473	\$	1,000,000	Female	75	150	(U.S.A.)	AA-
474	\$	500,000	Male	75 75	72	American General Life Insurance Company	A+
475	\$	250,000	Male	75 75	73	Genworth Life and Annuity Insurance Company	BB
476	\$	500,000	Male	75 75	95 125	Delaware Life Insurance Company	BBB+
477	\$	370,000	Female	75 74	125	Minnesota Life Insurance Company	A+
478	\$	500,000	Male	74	33	Midland National Life Insurance Company	A+
479	\$	3,000,000	Male	74	71	AXA Equitable Life Insurance Company	A+

					William Penn Life Insurance Company of New	
480	\$ 500,000	Male	74	61	York	AA-
					John Hancock Life Insurance Company	
481	\$ 2,500,000	Male	74	103	(U.S.A.)	AA-
482	\$ 500,000	Male	74	134	Pruco Life Insurance Company	AA-
483	\$ 8,600,000	Male	74	152	AXA Equitable Life Insurance Company	A+
484	\$ 3,000,000	Male	74	103	Transamerica Life Insurance Company	AA-
					John Hancock Life Insurance Company	
485	\$ 800,000	Male	74	122	(U.S.A.)	AA-
27						

	Fac	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
486	\$	1,500,000	Male	74	126	Lincoln National Life Insurance Company	AA-
487	\$	1,500,000	Male	74	126	Lincoln National Life Insurance Company	AA-
488	\$	1,500,000	Male	74	126	Lincoln National Life Insurance Company	AA-
489	\$	2,500,000	Male	74	136	Banner Life Insurance Company	AA-
490	\$	400,000	Male	74	80	Protective Life Insurance Company	AA-
						John Hancock Life Insurance Company	
491	\$	10,000,000	Male	74	144	(U.S.A.)	AA-
492	\$	1,784,686	Male	74	153	Transamerica Life Insurance Company	AA-
493	\$	250,000	Female	74	171	Protective Life Insurance Company	AA-
494	\$	500,000	Male	73	122	Ameritas Life Insurance Corporation	A+
495	\$	370,000	Male	73	122	Ameritas Life Insurance Corporation	A+
496	\$	750,000	Male	73	130	Security Life of Denver Insurance Company	A
497	\$	1,000,000	Female	73	120	United of Omaha Life Insurance Company	AA-
						William Penn Life Insurance Company of New	
498	\$	500,000	Male	73	106	York	AA-
499	\$	250,000	Male	73	18	Security Life of Denver Insurance Company	A
500	\$	100,000	Male	73	110	Protective Life Insurance Company	AA-
501	\$	500,000	Male	73	128	Metropolitan Life Insurance Company	A+
		,				Voya Retirement Insurance and Annuity	
502	\$	2,000,000	Male	73	120	Company	A
	-	_,,		, -		Voya Retirement Insurance and Annuity	
503	\$	1,500,000	Male	73	120	Company	A
504	\$	300,000	Male	73	114	Protective Life Insurance Company	AA-
505	\$	250,000	Male	73	68	American General Life Insurance Company	A+
506	\$	2,500,000	Male	73	104	American General Life Insurance Company	A+
200	Ψ	2,200,000	1,1410	7.5	101	John Hancock Life Insurance Company	11.
507	\$	2,000,000	Male	73	131	(U.S.A.)	AA-
207	Ψ	2,000,000	Marc	7.5	101	Commonwealth Annuity and Life Insurance	1111
508	\$	800,000	Male	73	84	Company	A-
509	\$	267,988	Male	73	52	Minnesota Life Insurance Company	A+
510	\$	300,000	Male	73	111	New England Life Insurance Company	AA-
511	\$	1,167,000	Male	73	50	Transamerica Life Insurance Company	AA-
512	\$	1,500,000	Male	73	108	Metropolitan Life Insurance Company	A+
513	\$	1,000,000	Female	73	144	Reliastar Life Insurance Company	A
514	\$	10,000,000	Male	73	118	AXA Equitable Life Insurance Company	A+
515	\$	1,000,000	Male	72	130	AIG Life Insurance Company	A+
516	\$	2,500,000	Male	72	51	Transamerica Life Insurance Company	AA-
517	\$	400,000	Male	72	195	Protective Life Insurance Company	AA-
	-	,			-,-	John Hancock Life Insurance Company	
518	\$	3,000,000	Male	72	75	(U.S.A.)	AA-
519	\$	2,000,000	Male	72	100	New York Life Insurance Company	AA+
520	\$	2,000,000	Male	72	100	New York Life Insurance Company	AA+
020	Ψ	_,000,000	1.1010	, –	100	John Hancock Life Insurance Company	1111
521	\$	5,000,000	Male	72	128	(U.S.A.)	AA-
522	\$	250,000	Female	72	108	Protective Life Insurance Company	AA-
523	\$	2,500,000	Male	72	114	Lincoln National Life Insurance Company	AA-
						John Hancock Life Insurance Company	
524	\$	2,500,000	Male	72	114	(U.S.A.)	AA-
525	\$	1,350,000	Male	72	100	Lincoln National Life Insurance Company	AA-
						· ·	

526	\$ 230,000	Male	72	117	Transamerica Life Insurance Company	AA-
527	\$ 139,398	Female	72	23	Lincoln National Life Insurance Company	AA-
528	\$ 190,000	Female	72	191	Protective Life Insurance Company	AA-
529	\$ 420,000	Male	72	131	Protective Life Insurance Company	AA-
530	\$ 75,000	Female	72	102	American General Life Insurance Company	A+
531	\$ 600,000	Male	72	84	AXA Equitable Life Insurance Company	A+
532	\$ 4,000,000	Male	72	141	MONY Life Insurance Company of America	A+
533	\$ 420,000	Male	72	122	RiverSource Life Insurance Company	A+
534	\$ 100,000	Male	72	137	Protective Life Insurance Company	AA-
28						

	Face	e		Age	LE		S&P
	Am	ount	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
535	\$	250,000	Male	71	50	Protective Life Insurance Company	AA-
536	\$	650,000	Female	71	72	Security Life of Denver Insurance Company	A
537	\$	500,000	Male	71	120	Ohio National Life Assurance Corporation	AA-
538	\$	232,000	Male	71	179	Protective Life Insurance Company	AA-
539	\$	185,000	Male	71	131	Genworth Life and Annuity Insurance Company	BB
540	\$	40,000	Male	71	31	Banner Life Insurance Company	AA-
541	\$	750,000	Male	71	125	Transamerica Life Insurance Company	AA-
542	\$	1,250,000	Male	71	99	West Coast Life Insurance Company	AA-
543	\$	1,500,000	Female	71	153	Pruco Life Insurance Company	AA-
544	\$	5,000,000	Male	71	91	Transamerica Life Insurance Company	AA-
545	\$	500,000	Male	71	92	Transamerica Life Insurance Company	AA-
						North American Company for Life And Health	
546	\$	500,000	Male	71	92	Insurance	A+
						John Hancock Life Insurance Company	
547	\$	300,000	Male	71	195	(U.S.A.)	AA-
548	\$	100,000	Male	71	44	Genworth Life and Annuity Insurance Company	BB
549	\$	150,000	Male	71	34	Protective Life Insurance Company	AA-
550	\$	150,000	Male	71	34	AXA Equitable Life Insurance Company	A+
						John Hancock Life Insurance Company	
551	\$	1,000,000	Male	71	54	(U.S.A.)	AA-
552	\$	202,700	Male	71	117	Farmers New World Life Insurance Company	N/A
553	\$	5,000,000	Male	71	151	Metropolitan Life Insurance Company	A+
554	\$	250,000	Female	70	120	Ohio National Life Assurance Corporation	AA-
						John Hancock Life Insurance Company	
555	\$	2,000,000	Male	70	172	(U.S.A.)	AA-
556	\$	400,000	Male	70	161	Lincoln National Life Insurance Company	AA-
557	\$	100,000	Male	70	101	Massachusetts Mutual Life Insurance Company	AA+
558	\$	92,000	Female	70	199	Protective Life Insurance Company	AA-
559	\$	175,000	Female	70	111	Lincoln National Life Insurance Company	AA-
560	\$	1,500,000	Male	70	71	Lincoln National Life Insurance Company	AA-
561	\$	250,000	Male	70	184	Lincoln National Life Insurance Company	AA-
562	\$	1,500,000	Male	70	105	Midland National Life Insurance Company	A+
563	\$	500,000	Male	70	111	Lincoln Benefit Life Company	BBB+
564	\$	700,000	Male	70	116	Massachusetts Mutual Life Insurance Company	AA+
						North American Company for Life And Health	
565	\$	750,000	Male	69	134	Insurance	A+
566	\$	1,000,000	Male	69	191	AXA Equitable Life Insurance Company	A+
567	\$	1,200,000	Male	69	126	Massachusetts Mutual Life Insurance Company	AA+
568	\$	2,500,000	Male	69	161	Pruco Life Insurance Company	AA-
569	\$	2,500,000	Male	69	161	Pruco Life Insurance Company	AA-
570	\$	4,000,000	Male	69	133	MetLife Insurance Company USA	A+
551	Φ.	7 00 000	3.6.1	60	40	Voya Retirement Insurance and Annuity	
571	\$	500,000	Male	69	42	Company	A
572	\$	1,000,000	Male	69	87	Protective Life Insurance Company	AA-
573	\$	2,000,000	Male	69	113	Transamerica Life Insurance Company	AA-
574 575	\$	1,000,000	Male	69	113	Genworth Life Insurance Company	BB
575 576	\$	250,000	Female	69	158	Protective Life Insurance Company	AA-
576	\$	1,000,000	Male	69	163	Accordia Life and Annuity Company	A-
577	\$	1,000,000	Male	69	61	Protective Life Insurance Company	AA-

578	\$ 1,000,000	Male	69	131	Transamerica Life Insurance Company	AA-
579	\$ 1,000,000	Male	69	131	Protective Life Insurance Company	AA-
580	\$ 156,538	Female	69	107	New York Life Insurance Company	AA+
581	\$ 2,000,000	Male	69	51	Metropolitan Life Insurance Company	A+
582	\$ 2,000,000	Male	69	51	Metropolitan Life Insurance Company	A+
					John Hancock Life Insurance Company	
583	\$ 1,000,000	Male	69	153	(U.S.A.)	AA-
29						

	Face			Age	LE		S&P
	Amo	unt	Gender	$(ALB)^{(1)}$	$(mo.)^{(2)}$	Insurance Company	Rating
584	\$	400,000	Female	69	142	AXA Equitable Life Insurance Company	A+
585	\$	300,000	Male	69	90	Protective Life Insurance Company	AA-
586	\$	1,000,000	Male	68	138	Transamerica Life Insurance Company	AA-
587	\$	250,000	Female	68	75	Transamerica Life Insurance Company	AA-
						Northwestern Mutual Life Insurance	
588	\$	750,000	Male	68	161	Company	AA+
						John Hancock Life Insurance Company	
589	\$	2,000,000	Male	68	173	(U.S.A.)	AA-
590	\$	150,000	Male	68	117	Protective Life Insurance Company	AA-
		•				William Penn Life Insurance Company of	
591	\$	600,000	Male	68	88	New York	AA-
		,				John Hancock Life Insurance Company	
592	\$	5,616,468	Male	68	180	(U.S.A.)	AA-
	т.	2,020,100				John Hancock Life Insurance Company	
593	\$	1,100,000	Male	68	156	(U.S.A.)	AA-
0,0	Ψ	1,100,000	TVICIO	00	100	John Hancock Life Insurance Company	1111
594	\$	3,000,000	Male	68	193	(U.S.A.)	AA-
595	\$	400,000	Male	67	191	Lincoln National Life Insurance Company	AA-
596	\$	3,000,000	Male	67	100	Reliastar Life Insurance Company	A
597	\$ \$	2,000,000	Male	67	100	AXA Equitable Life Insurance Company	A+
598	\$ \$	2,000,000	Male	67	100	AXA Equitable Life Insurance Company	A+
599	\$	1,000,000	Male	67	48	Lincoln National Life Insurance Company	AA-
600	\$ \$	1,000,000	Male	67	78	Transamerica Life Insurance Company	AA-
601	\$ \$	350,000	Female	67	85	Assurity Life Insurance Company	N/A
001	Ф	330,000	Pennaie	07	63	· · · · · · · · · · · · · · · · · · ·	1 \ //A
602	\$	5,000,000	Male	67	105	Athene Annuity & Life Assurance	A-
002	Ф	3,000,000	Male	07	103	Company	A-
602	¢	1 000 000	Male	67	1.40	Sun Life Assurance Company of Canada	A A
603	\$	1,000,000		67	149	(U.S.)	AA-
604	\$	800,000	Male	67	129	Lincoln National Life Insurance Company	AA-
605	\$	800,000	Male	67	129	Lincoln National Life Insurance Company	AA-
(0)	ф	220.725	F 1	67	107	Hartford Life and Annuity Insurance	DDD.
606	\$	229,725	Female	67	107	Company	BBB+
607	\$	490,000	Male	67	97 25	AXA Equitable Life Insurance Company	A+
608	\$	220,581	Male	67	25	American General Life Insurance Company	A+
609	\$	1,000,000	Male	67	109	The Savings Bank Life Insurance Company	
640	.	220 000			1.60	of Massachusetts	A-
610	\$	320,000	Male	67	162	Transamerica Life Insurance Company	AA-
611	\$	250,000	Male	67	163	Pruco Life Insurance Company	AA-
						Genworth Life and Annuity Insurance	
612	\$	125,000	Male	67	50	Company	BB
613	\$	250,000	Male	67	199	Zurich Life Insurance Company	AA-
614	\$	650,000	Male	67	185	Lincoln National Life Insurance Company	AA-
615	\$	400,000	Male	66	132	Jackson National Life Insurance Company	AA
616	\$	500,000	Female	66	171	Banner Life Insurance Company	AA-
617	\$	350,000	Male	66	97	RiverSource Life Insurance Company	A+
618	\$	200,000	Male	66	163	Prudential Insurance Company of America	AA-
619	\$	200,000	Male	66	163	Prudential Insurance Company of America	AA-
620	\$	750,000	Male	66	128	Pacific Life Insurance Company	A+
621	\$	500,000	Male	66	136	Transamerica Life Insurance Company	AA-

622	\$ 500,000	Female	66	132	AIG Life Insurance Company	A+
623	\$ 265,000	Male	65	159	Protective Life Insurance Company	AA-
624	\$ 10,000,000	Male	65	65	Lincoln National Life Insurance Company	AA-
625	\$ 540,000	Male	65	172	West Coast Life Insurance Company	AA-
	\$ 1,272,077,891					

⁽¹⁾ Person's age on last birthday (ALB)

⁽²⁾ The insured's life expectancy estimate, other than for a small face value insurance contract (i.e., a contract with \$1 million in face value benefits or less), is the average of two life expectancy estimates provided by independent third-party medical-actuarial underwriting firms at the time of purchase, actuarially adjusted through the measurement date. Numbers in this column represent months.

OTHER INFORMATION

Origination, Underwriting and Technology

We focus on purchasing high quality life insurance assets through our origination practices and underwriting procedures. In general, these practices and procedures strive to meet published guidelines for rated securitizations of life insurance portfolios. At the same time, we seek innovative value-added tools, services, and methodologies to improve both the accuracy and efficiency with which we evaluate and acquire life insurance assets.

Since 2013, we have focused on developing our direct origination channels through which we may purchase life insurance policies without the involvement of a life settlement broker, thereby eliminating commission costs and timing delays in the acquisition. We expect to continue allocating considerable resources towards developing our direct origination channels, primarily by outreach and relationship building with financial advisors (who may also sell our investment securities), life insurance agents, and consumers.

Our success in direct origination has presented us with the opportunity to purchase a greater number of "small face" life insurance policies with a face value benefit of \$1,000,000 or less. We believe this opportunity is meaningful since the majority of life insurance policies outstanding are small face policies, and policy diversification is critical in obtaining normalized actuarial performance. Historically, however, small face policies have not been available to purchasers of life insurance contracts because the secondary market industry participants have significantly relied on life settlement brokers who are paid a commission determined as a percentage of the face value benefit of the purchased policy, to present purchase opportunities. Not surprisingly, because larger commissions are associated with larger face value life insurance contracts, brokers have focused on larger contracts and the industry has developed origination practices and underwriting procedures to accommodate such practices. As a result, the industry's traditional approaches to underwriting and purchasing life insurance assets are ill suited for small face policies. For example, procuring complete medical records, two separate life expectancy reports, and engaging in related activities, can be time consuming and expensive, and these same costs cannot be justified when purchasing smaller life insurance assets.

To more fully realize the potential of the direct origination channel we have built, we have developed what we believe to be an efficient, cost-effective, and reliable method of underwriting and purchasing small face policies. In sum, our method is focused on obtaining enough medical information to generate reliable life expectancy estimates, and thereby make informed purchase decisions. We expect to refine this process over time and, to the extent possible, use new technologies to enhance this process and our overall business.

To that end, we have recently announced the execution of our option to exclusively license "DNA Methylation Based Predictor of Mortality" technology from the University of California, Los Angeles (UCLA) and discovered by Dr. Steven Horvath. In 2013, Dr. Horvath reported that human cells have a mechanism that records "biological age" progression, based on DNA methylation that is independent from "chronological age." In 2016, Dr. Horvath discovered a specific set of DNA methylation-based bio-markers that are highly predictive of all-cause mortality. The discovery

was made through a statistical analysis of bio-markers found in DNA samples from over 13,000 individuals whose health was studied for decades. The implications of Dr. Horvath's discovery are simple and profound: Individual lifespans can now be estimated with significantly greater precision. We intend to implement aspects of this technology in our underwriting protocols and to explore how this technology may have commercial value to the primary life insurance, long-term care, and annuity businesses.

31

RISK FACTOR UPDATE

The following risk factors are hereby added to the prospectus. You should read these risk factors carefully and in conjunction with the other risk factors disclosed in the prospectus.

Accuracy of the life expectancy estimates and mortality curves we use for small face contracts could have a material and adverse effect on our results of operation and financial condition.

As of September 30, 2016, we owned 306 "small face" life insurance policies (i.e., a contract with \$1 million in face value benefits or less) having \$164 million in face value of insurance benefits. The underwriting processes and mortality curves we use to evaluate, price and purchase small face contracts may be different from, and, as a result, may not be as reliable as, the processes we use for life insurance contracts with larger face values of benefits. While we obtain life expectancy reports from third-party evaluators based on medical evidence, the processes used to develop these life expectancy reports are less extensive than traditional methods. Although we have professional actuarial guidance in the use and application of mortality curves to price and value small face contracts, the application of these mortality curves may not be as reliable as or more subject to adjustment than the processes we use for larger face value of benefits. As the face value of our small face contracts increases relative to the size of our total portfolio, the accuracy with which we have estimated life expectancies and mortality curves for these contracts will become increasingly material to our business. Any shortcomings in the processes we have used to evaluate, price, purchase and value the small face contracts we own could have a material and adverse effect on our results of operation and financial condition. Any such outcomes would likely have a negative and possibly material effect on the price of our common stock and our ability to satisfy our debts.

We may in the future rely, in part, on new and unproven technology as part of our underwriting processes. If the mortality predictions we obtain through use of this technology proves inaccurate, our results of operation and financial condition could be materially and adversely affected.

We recently exercised our option to license, on an exclusive basis, new technology that we believe may be applied to assist us with the mortality predictions in the course of underwriting and valuing life insurance contracts. This technology, however, has not yet been commercially applied in the manner we envision, and it possible that we will be unable to elicit more accurate mortality predictions through its use. It is also possible that the mortality predictions we obtain through the use of this technology will prove inaccurate, and perhaps materially so. In such a case, our failure to accurately forecast mortalities could have a material and adverse effect on our results of operation and financial condition, which could in turn materially and negatively affect the price of our common stock and our ability to satisfy our debts.

The technology we license may subject us to claims of infringement or invalidity from third parties, and the magnitude of this risk to our business generally rises if and as we become more successful in employing and relying on the technology. Any such claims would be complex and costly, and adverse outcomes could undermine

the competitive advantages we seek.

Our reliance on technology will subject us to the risk that other parties may assert, rightly or wrongly, that our intellectual property rights are invalid or violate the rights of those parties, as well as the risk that our intellectual property rights will be infringed upon by third parties. Any outcome that invalidates our intellectual property rights or that otherwise diminishes the competitive advantages obtained, at least in part, through the use of those rights could have a material and adverse effect on our competitive position and our prospects.

32

FINANCIAL INFORMATION

GWG HOLDINGS, INC.

Table of Contents

	Page
Condensed Consolidated Balance Sheets as of September 30, 2016 (unaudited) and December	
31, 2015	F-1
Condensed Consolidated Statements of Operations for the nine months ended September 30,	
2016 and 2015 (unaudited)	F-2
Condensed Consolidated Statement of Cash Flows for the nine months ended September 30,	
2016 and 2015 (unaudited)	F-3
Notes to Condensed Consolidated Financial Statements	F-6
F-1	

GWG HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

	2016	ember 30, adited)	Decer 2015	mber 31,	
Cash and cash equivalents	\$	18,773,828	\$	34,425,105	
Restricted cash		15,688,025		2,341,900	
Investment in life insurance contracts, at fair		477,585,100		256 640 715	
value Secured MCA advances		6,113,831		356,649,715	
Life insurance contract benefits receivable		6,129,022		_	
Other assets		3,131,107		2,461,045	
TOTAL ASSETS	\$	527,420,913	\$	395,877,765	
LIABILITIES &	STOCK	KHOLDERS' EQUITY			
LIABILITIES	01001	<u> </u>			
Senior Credit Facilities	\$	63,699,385	\$	63,279,596	
Series I Secured Notes		17,553,307		23,287,704	
L Bonds		379,858,737		276,482,796	
Accounts payable		2,442,449		1,517,440	
Interest payable		13,633,640		12,340,061	
Other accrued expenses		645,343		1,060,786	
Deferred taxes, net	ф	3,242,586	Ф	1,763,968	
TOTAL LIABILITIES	\$	481,075,447	\$	379,732,351	
STOCKHOLDERS' EQUITY					
CONVERTIBLE PREFERRED STOCK (par value \$0.001; shares authorized 40,000,000; shares outstanding 2,649,665 and 2,781,735; liquidation preference of \$19,872,000 and \$20,863,000 on September 30, 2016 and December 31, 2015, respectively)		19,772,931		20,784,841	
REDEEMABLE PREFERRED STOCK (par value \$0.001; shares authorized 100,000; shares outstanding 33,201; liquidation preference of \$33,176,600 on September 30, 2016)		33,176,600		_	
COMMON STOCK (par value \$0.001: shares authorized 210,000,000; shares issued and outstanding 5,980,190 and 5,941,790 on September 30, 2016 and December 31, 2015) Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS' EQUITY		5,980 15,226,449 (21,836,494) 46,345,466		5,942 17,149,391 (21,794,760) 16,145,414	

TOTAL LIABILITIES & EQUITY \$ 527,420,913 \$ 395,877,765 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

F-2

GWG HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

	Three Months Ended September 30, 2016			Se	September 30, 2015			Nine Months Ended September 30, 2016			ptember 30,	
REVENUE Gain on life insurance contracts, net MCA income Interest and other income TOTAL REVENUE	\$	13,509,755 286,225 124,998 13,920,978		\$	8,189,261 — 93,841 8,283,102		\$	51,606,815 654,441 341,098 52,602,354		\$	33,446,556 — 233,516 33,680,072	
EXPENSES Interest expense Employee compensation and benefits Legal and professional fees Other expenses TOTAL EXPENSES		11,983,968 2,912,463 586,830 2,863,212 18,346,473			8,650,149 2,308,246 822,077 2,231,341 14,011,813			32,009,934 8,450,168 3,097,312 7,608,057 51,165,471			23,149,030 6,180,886 1,988,261 5,646,402 36,964,579	
INCOME (LOSS) BEFORE INCOME TAXES INCOME TAX EXPENSE (BENEFIT) NET LOSS	\$	(4,425,495 (1,428,130 (2,997,365)		(5,728,711 (2,097,633 (3,631,078)	\$	1,436,883 1,478,617 (41,734)	\$	(3,284,507 (664,905 (2,619,602)
Loss attributable to preferred shareholders INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS NET INCOME (LOSS) PER	\$	421,026 (2,576,339			343,644 (3,287,434		\$	1,103,896 1,062,162	,	\$	1,041,648	
SHARE Basic Diluted	\$ \$	(0.50 (0.50)		(0.61 (0.61)		(0.01 0.13)	\$ \$	(0.44 (0.44)
WEIGHTED AVERAGE SHARES OUTSTANDING Basic Diluted		5,978,322 5,978,322			5,937,320 5,937,320			5,962,938 8,092,196			5,894,956 5,894,956	

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

GWG HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited)

	Three Months Ended September 30, 2016	September 30, 2015	Nine Months Ended September 30, 2016	September 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net	\$ (2,997,365)	\$ (3,631,078)	\$ (41,734)	\$ (2,619,602)
loss to net cash flows from operating activities: Gain on life insurance contracts Amortization of deferred	(21,073,226)	(14,516,881)	(53,846,155)	(26,651,363)
financing and issuance costs Deferred income taxes Preferred stock dividends	2,765,743 (1,428,130)	1,933,776 (1,916,686)	6,077,905 1,478,617	1,891,772 (664,905)
payable (Increase) decrease in operating assets:	333,565	173,993	663,614	509,225
Life insurance contract benefits receivable Other assets Increase (decrease) in operating	700,000 419,836	2,142,986 (417,990)	(6,129,022) (617,630)	1,392,986 (774,539)
liabilities: Due to related party Accounts payable and other	(80,949)	_	(182,730)	_
accrued expenses NET CASH FLOWS USED IN	(3,216,990)	2,534,269	(2,024,234)	3,836,715
OPERATING ACTIVITIES	(24,577,516)	(13,697,611)	(54,621,369)	(23,079,711)
CASH FLOWS FROM INVESTING ACTIVITIES Investment in life insurance				
contracts Carrying value of matured life	(25,770,326)	(13,626,842)	(74,470,362)	(23,850,860)
insurance contracts Investment in Secured MCA	1,078,889	80,000	7,381,132	3,822,983
advances Proceeds from Secured MCA	(1,965,896)	_	(7,613,310)	_
advances NET CASH FLOWS USED IN	220,911	_	1,246,703	_
INVESTING ACTIVITIES	(26,436,422)	(13,546,842)	(73,455,837)	(20,027,877)
CASH FLOWS FROM FINANCING ACTIVITIES Net borrowings on (repayments				
of) Senior Credit Facilities Payments for redemption of	(10,761,048)	_	6,238,952	(7,150,000)
Series I Secured Notes	(541,275)	(890,586)	(6,264,018)	(4,508,130)

Edgar Filing: GWG Holdings, Inc. - Form 424B3

Bonds 64,350,430 37,122,127 135,477,090 87,620,48	
Dormants for issuance and)4)
Payments for issuance and)4)
redemption of L Bonds (14,373,447) (19,363,047) (37,036,922) (32,376,10	
Proceeds from (increase in)	
restricted cash (4,527,232) 651,630 (13,346,126) (2,975,50°	7)
Issuance of common stock 31,515 — 244,185 582,000	
Proceeds from issuance of	
preferred stock 20,786,332 — 31,287,541 —	
Payments for issuance and	
redemption of preferred stock (2,556,859) (21,187) (4,174,773) (295,185)
NET CASH FLOWS	
PROVIDED BY FINANCING	
ACTIVITIES 52,408,416 17,498,937 112,425,929 40,897,55	7
NET INCREASE	
(DECREASE) IN CASH AND	
CASH EQUIVALENTS 1,394,478 (9,745,516) (15,651,277) (2,210,03)	1)
CASH AND CASH	
EQUIVALENTS	
BEGINNING OF PERIOD 17,379,350 38,198,189 34,425,105 30,662,70	
END OF PERIOD \$ 18,773,828 \$ 28,452,673 \$ 18,773,828 \$ 28,452,67	3

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

GWG HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS — CONTINUED (unaudited)

	Three Months Ended September 30, 2016		September 30, 2015		Nine Months Ended September 30, 2016		September 30, 2015	
SUPPLEMENTAL								
DISCLOSURES OF CASH FLOW								
INFORMATION								
Interest and preferred dividends								
paid	\$	11,516,000	\$	5,385,000	\$	28,683,000	\$	18,529,000
Premiums paid	\$	11,785,000	\$	6,603,000	\$	29,225,000	\$	19,069,000
Stock-based compensation	\$	162,000	\$	176,000	\$	213,000	\$	208,000
NON-CASH INVESTING AND								
FINANCING ACTIVITIES								
Series I Secured Notes:								
Conversion of accrued interest and								
commissions payable to principal	\$	47,000	\$	61,000	\$	234,000	\$	188,000
L Bonds:								
Conversion of accrued interest and								
commissions payable to principal	\$	854,000	\$	491,000	\$	1,515,000	\$	929,000
Issuance of Series A Preferred								
Stock in lieu of cash dividends	\$	170,000	\$	172,000	\$	509,000	\$	507,000
Investment in life insurance								
contracts included in accounts								
payable	\$	1,603,000	\$	559,000	\$	1,603,000	\$	559,000

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(1) Nature of Business and Summary of Significant Accounting Policies

Nature of Business — Through its wholly owned subsidiaries, GWG Holdings, Inc. owns a portfolio of life insurance contracts. As of the date of this report, our portfolio had an aggregate fair value of \$477.6 million. We earn income from changes in the fair value of our portfolio and through the benefits we receive from the life insurance contracts we own. We are also involved in other lines of business, including a business that collects commissions for facilitating the conversion of term life insurance contracts into universal, or permanent, life insurance, and a business that participates in the merchant cash advance industry by advancing sums to merchants and lending money to businesses that advance sums to merchants. Operating results for the three- and nine-month periods included in this report are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

GWG Holdings, Inc. and all of its subsidiaries are incorporated and organized in Delaware. Unless the context otherwise requires or we specifically so indicate, all references in these footnotes to "we," "us," "our," "our Company," "GWG or the "Company" refer to GWG Holdings, Inc. and its subsidiaries collectively and on a consolidated basis. References to the full names of particular entities, such as "GWG Holdings, Inc." or "GWG Holdings," are meant to refer only to the particular entity referenced.

Use of Estimates — The preparation of our consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenue during the reporting period. The Company regularly evaluates estimates and assumptions, which are based on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. The most significant estimates with regard to these consolidated financial statements relate to (1) the determination of the assumptions used in estimating the fair value of our investments in life insurance contracts, and (2) the value of our deferred tax assets and liabilities.

Cash and Cash Equivalents — We consider cash in demand deposit accounts and temporary investments purchased with an original maturity of three months or less to be cash equivalents. We maintain our cash and cash equivalents with highly rated financial institutions. The balances in our bank accounts may exceed Federal Deposit Insurance Corporation limits. We periodically evaluate the risk of exceeding insured levels and may transfer funds as we deem appropriate.

Life Insurance Contracts — ASC 325-30, Investments in Insurance Contracts ("ASC 325-30"), permits a reporting entity to account for its investments in life insurance contracts using either the investment method or the fair value method. We elected to use the fair value method to account for our life insurance contracts. Under the fair value method, we recognize our initial investment at the purchase price. At each subsequent reporting period, we re-measure the investment at fair value in its entirety and recognize the change in fair value as revenue in the current period net of premiums paid. We use the term "life insurance contracts" to have the same meaning as "life insurance policies."

We also recognize realized gain (revenue) from a life insurance contract upon one of the two following events: (1) our receipt of notice or verified mortality of the insured; or (2) our sale of the contract, filing of change-of-ownership forms and receipt of payment. In the case of mortality, the gain (or loss) we recognize is the difference between the contract benefits and the carrying values of the contract once we receive notice or verify the mortality of the insured. In the case of a contract sale, the gain (or loss) we recognize is the difference between the sale price and the carrying value of the contract on the date of our receipt of sale proceeds.

In a case where our acquisition of a contract is not complete as of a reporting date, but we have nonetheless advanced direct costs and deposits for the acquisition, those costs and deposits are recorded as "other assets" on our balance sheet until the acquisition is complete and we secured title to the contract. On September 30, 2016 and December 31, 2015, a total of \$34,000 and \$31,000, respectively, of our "other assets" comprised direct costs and deposits that we advanced for contract acquisitions.

Other Assets — GWG acquired the exclusive option to license "DNA Methylation Based Predictor of Mortality" technology from the University of California, Los Angeles (UCLA). The technology was discovered by Dr. Steven Horvath and is featured in the September 2016 edition of Aging. In 2013, Dr. Horvath reported that human cells

F-6

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(1) Nature of Business and Summary of Significant Accounting Policies (cont.)

have a mechanism that records biological aging progression based on DNA methylation that is independent from chronological aging progression. In 2016, Dr. Horvath discovered a specific set of DNA methylation-based bio-markers that are highly predictive of all-cause mortality. The discovery was made through a statistical analysis of bio-markers found in DNA samples from over 13,000 individuals whose health had been studied for decades. The implications of Dr. Horvath's discovery are simple and profound: A biostatistician can review a specific set of identified bio-markers and develop a highly predictive analytical model of an individual's lifespan. The cost of entering into this exclusive option agreement is listed as "other assets".

Deferred Financing and Issuance Costs — Loans advanced to us under our senior credit facilities, as described in Notes 5 and 6, are reported net of financing costs, which are amortized using the straight-line method over the term of the facility. The Series I Secured Notes and L Bonds, as respectively described in Notes 7 and 8, are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of those borrowings. The Series A Preferred Stock, as described in Note 9, is reported net of issuance costs, sales commissions (including the fair value of warrants issued) and other direct expenses, all of which were fully amortized using the interest method as of December 31, 2015. Selling and issuance costs of Redeemable Preferred Stock and MCA Preferred Stock, described in Notes 10 and 11, are netted against additional paid-in-capital.

Earnings (loss) per Share — Basic earnings (loss) per share attributable to non-redeemable interests are calculated using the weighted-average number of shares outstanding during the reported period. Diluted earnings (loss) per share are calculated based on the potential dilutive impact of our outstanding Series A Preferred Stock, Redeemable Preferred Stock, warrants and stock options.

Recently Adopted Pronouncements — On April 7, 2015, the FASB issued Accounting Standards Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"), as part of its simplification initiative. ASU 2015-03 changes the presentation of debt issuance costs by presenting those costs in the balance sheet as a direct deduction from the related debt liability. Amortization of the costs is reported as interest expense. We adopted ASU 2015-03 effective January 1, 2016, as required for public reporting entities.

Reclassification — Certain 2015 amounts have been reclassified to conform to ASU 2015-03, and that adoption reduced our assets, together with a corresponding reduction to our liabilities, by approximately \$2,288,000 as of December 31, 2015. There was no impact on our statements of operations in 2015, and these reclassifications had no effect on our reported consolidated net income or loss for prior periods.

(2) Restrictions on Cash

Under the terms of our senior credit facilities (discussed in Notes 5 and 6), we are required to maintain collection and escrow accounts that are used to fund the acquisition of contracts, pay annual contract premiums, pay interest and other charges under the facility, and collect contract benefits. The agent for the lender authorizes the disbursements from these accounts. At September 30, 2016 and December 31, 2015, there was a balance of \$15,688,000, and \$2,342,000, respectively, in these restricted cash accounts.

(3) Investment in Life Insurance Contracts

Life insurance contracts are valued based on unobservable inputs that are significant to their overall fair value. Changes in the fair value of these contracts are recorded as gain or loss on life insurance contracts, net of cash

premiums paid on those contracts, in our consolidated statements of operations. Fair value is determined on a discounted cash flow basis that incorporates life expectancy assumptions derived from reports obtained from widely accepted life expectancy providers, assumptions relating to cost-of-insurance (premium) rates and other assumptions. The discount rate we apply incorporates current information about discount rate applied by other reporting companies owning portfolios of life insurance contracts, the discount rates observed in the life insurance secondary market, market interest rates, our credit exposure to the insurance companies that issued the life insurance contracts and management's estimate of the risk premium a purchaser would require to receive the future cash flows derived from our portfolio as a whole.

(3) Investment in Life Insurance Contracts (cont.)

As a result of management's analysis, discount rates of 11.07% and 11.09% were applied to our portfolio as of September 30, 2016 and December 31, 2015, respectively.

We recognized life insurance benefits of \$5,300,000 and \$357,000 during the three months ended September 30, 2016 and 2015, respectively, related to contracts with a carrying value of \$1,078,000 and \$80,000, respectively, and as a result recorded realized gains of \$4,221,000 and \$277,000. We recognized life insurance benefits of \$34,367,000 and \$29,732,000 during the nine months ended September 30, 2016 and 2015, respectively, related to contracts with a carrying value of \$7,381,000 and \$3,823,000, respectively, and as a result recorded realized gains of \$26,986,000 and \$25,909,000.

Reconciliation of gain on life insurance contracts:

	Th	nree Months Ended			Ni	ne Months Ended		
	Se	eptember 30,			Se	ptember 30,		
	20)16	20	15	20	16	20	15
Change in fair value	\$	21,073,000	\$	14,517,000	\$	53,846,000	\$	26,651,000
Premiums and other fees		(11,784,000)		(6,605,000)		(29,225,000)		(19,114,000)
Contract maturities		4,221,000		277,000		26,986,000		25,909,000
Gain on life insurance								
contracts, net	\$	13,510,000	\$	8,189,000	\$	51,607,000	\$	33,446,000

We currently estimate that premium payments and servicing fees required to maintain our current portfolio of life insurance contracts in force for the next five years, assuming no mortalities, are as follows:

					Prer	niums
					and	
Years Ending December 31,	Premiums		Servicing		Serv	vicing Fees
Three months ending December 31, 2016	\$	10,449,000	\$	188,000	\$	10,637,000
2017		43,155,000		750,000		43,905,000
2018		46,847,000		750,000		47,597,000
2019		50,813,000		750,000		51,563,000
2020		56,633,000		750,000		57,383,000
2021		63,222,000		750,000		63,972,000
	\$	271,119,000	\$	3,938,000	\$	275,057,000

Management anticipates funding the premium payments estimated above with proceeds from our senior credit facilities, proceeds from additional debt and equity financing, and proceeds from maturities of life insurance contracts. The proceeds of these capital sources may also be used for the purchase, financing, and maintenance of additional life insurance contracts.

(4) Fair Value Definition and Hierarchy

ASC 820, Fair Value Measurement ("ASC 820"), establishes a hierarchical disclosure framework that prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is affected by a number of factors, including the type of investment, the characteristics specific to the investment and the state of the marketplace, including the existence and transparency of transactions between market participants. Assets and liabilities with readily available and actively quoted prices, or for which fair value can be

measured from actively quoted prices in an orderly market, generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value. ASC 820 maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring the use of observable inputs whenever available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect assumptions about how market participants price an asset or liability developed based on the best available information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(4) Fair Value Definition and Hierarchy (cont.)

The hierarchy is broken down into three levels based on the observability of inputs as follows:

- Level 1 Valuations based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.
- Level 2 Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
- Level 3 Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The availability of observable inputs can vary by types of assets and liabilities and is affected by a wide variety of factors, including, for example, whether an instrument is established in the marketplace, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by management in determining fair value is greatest for assets and liabilities categorized in Level 3.

Level 3 Valuation Process

The estimated fair value of our portfolio of life insurance contracts is determined on a quarterly basis by our portfolio management committee, taking into consideration changes in discount rate assumptions, estimated premium payments and life expectancy estimate assumptions, as well as any changes in economic and other relevant conditions. The discount rate incorporates (i) current information about discount rate applied by other reporting companies owning portfolios of life insurance contracts, (ii) the discount rates observed in the life insurance secondary market, (iii) market interest rates, (iv) our credit exposure to the insurance company that issued the life insurance contract and (v) management's estimate of the risk premium a purchaser would require to receive the future cash flows derived from our portfolio as a whole.

These inputs are then used to estimate the discounted cash flows from the portfolio using the Model Actuarial Pricing System probabilistic portfolio price model, which estimates the cash flows using various mortality probabilities and scenarios. The valuation process includes a review by senior management as of each valuation date. We also engage a third-party expert to independently test the accuracy of the valuations using the inputs we provide on a quarterly basis. See Exhibit 99.1 filed herewith.

The following table reconciles the beginning and ending fair value of our Level 3 investments in our portfolio of life insurance contracts for the periods ended September 30, as follows:

	Three months ended September 30,		Nine months ended September 30,	
	2016	2015	2016	2015
Beginning balance	\$ 431,820,000	\$ 301,499,000	\$ 356,650,000	\$ 282,883,000
Purchases	25,770,000	13,626,000	74,470,000	23,851,000
Maturities (carrying				
value)	(1,078,000)	(80,000)	(7,381,000)	(3,823,000)

Net change in fair value	21,073,000	14,517,000	53,846,000	26,651,000
Ending balance				
(September 30)	\$ 477,585,000	\$ 329,562,000	\$ 477,585,000	\$ 329,562,000

We periodically update the independent life expectancy estimates on the insured lives in our portfolio, other than insured lives covered under small face amount contracts (i.e., \$1 million in face value benefits or less), on a continuous rotating three-year cycle. Accordingly, we update life expectancies for approximately one-twelfth of our portfolio each quarter.

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(4) Fair Value Definition and Hierarchy (cont.)

The following table summarizes the inputs utilized in estimating the fair value of our portfolio of life insurance contracts:

	As of September 30,	As of December 31,
	2016	2015
Weighted-average age of insured, years	81.8	82.6
Weighted-average life expectancy, months	81.8	79.3
Average face amount per contract	\$ 2,035,000	\$ 2,386,000
Discount rate	11.07	% 11.09 %

These assumptions are, by their nature, inherently uncertain and the effect of changes in estimates may be significant. For example, if the life expectancy estimates were increased or decreased by four and eight months on each outstanding contract, and the discount rates were increased or decreased by 1% and 2%, while all other variables were held constant, the fair value of our investment in life insurance contracts would increase or (decrease) as summarized below:

Change in Fair Value of the Investment in Life Insurance Contracts

	Change in life expe	ectancy estimates		
	minus	minus	plus	plus
	8 months	4 months	4 months	8 months
September 30, 2016	\$ 64,713,000	\$ 32,215,000	\$ (31,450,000)	\$ (62,258,000)
December 31, 2015	\$ 48,339,000	\$ 24,076,000	\$ (23,501,000)	\$ (46,482,000)
	Change in discount	rate		
	minus 2%	minus 1%	plus 1%	plus 2%
September 30, 2016	\$ 50,097,000	\$ 23,990,000	\$ (22,096,000)	\$ (42,492,000)
December 31, 2015	\$ 35,024,000	\$ 16,786,000	\$ (15,485,000)	\$ (29,803,000)
Other Fair Value Conside	erations			

The carrying value of receivables, prepaid expenses, accounts payable and accrued expenses approximate fair value due to their short-term maturities and low credit risk. Using the income-based valuation approach, the estimated fair value of our Series I Secured Notes and L Bonds, having a combined aggregate face value of \$402,416,000 as of September 30, 2016, is approximately \$414,023,000 based on a weighted-average market interest rate of 6.36%. The carrying value of the senior credit facilities reflects interest charged at the commercial paper rate or 12-month LIBOR, as applicable, plus an applicable margin. The margin represents our credit risk, and the strength of the portfolio of life insurance contracts collateralizing the debt. The overall rate reflects market, and the carrying value of the facility approximates fair value.

Our wholly owned subsidiary GWG MCA Capital, Inc. ("GWG MCA") participates in the merchant cash advance by directly advancing sums to merchants and lending money, on a secured basis, to companies that advance sums to merchants. Each quarter, we review the carrying value of these advances and loans, and determine if an impairment reserve is necessary. At September 30, 2016, one of our secured loans to Nulook Capital LLC was potentially impaired. The secured loan to Nulook Capital LLC had an outstanding balance of \$3,215,000 and a loan loss reserve

of \$400,000 at September 30, 2016. We deem fair value to be the estimated collectible value on each loan or advance made from GWG MCA. Where we estimate the collectible amount to be less than the outstanding balance, we record a reserve for the difference.

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(4) Fair Value Definition and Hierarchy (cont.)

The following table summarizes outstanding warrants as of September 30, 2016:

	Warrants	Fair	value	Risk				
Month issued	issued	per	share	free rate		Volatility	/	Term
December 2011	68,937	\$	0.22	0.42	%	25.25	%	5 years
March 2012	38,130	\$	0.52	0.38	%	36.20	%	5 years
June 2012	161,840	\$	1.16	0.41	%	47.36	%	5 years
July 2012	144,547	\$	1.16	0.41	%	47.36	%	5 years
September 2012	2,500	\$	0.72	0.31	%	40.49	%	5 years
September 2014	16,000	\$	1.26	1.85	%	17.03	%	5 years
-	431.954							

⁽⁵⁾ Credit Facility — Autobahn Funding Company LLC

Through our subsidiaries GWG DLP Funding II, LLC ("DLP II") and GWG DLP Funding III, LLC ("DLP III"), we are party to a \$105 million revolving senior credit facility with Autobahn Funding Company LLC ("Autobahn"), with a maturity date of June 30, 2018. The facility is governed by a Credit and Security Agreement (the "Agreement"), and DZ Bank AG Deutsche Zentral-Genossenschaftsbank ("DZ Bank") acts as the agent for Autobahn under the Agreement. On September 14, 2016, we paid off the revolving senior credit facility in full with funds received from a new senior secured term loan with LNV Corporation as described in Note 6.

Advances under the facility bear interest at a commercial paper rate of the lender at the time of the advance, or at the lender's cost of borrowing plus 4.25%. We make interest payments on a monthly basis. The effective rate of interest was 5.42% at September 14, 2016 and 5.58% at December 31, 2015. The weighted-average effective interest rate, after excluding an unused line fee, was 5.46% and 5.42% for the three months ended September 30, 2016 and 2015, respectively, and 5.54% and 5.81% for the nine months ended September 30, 2016 and 2015, respectively.

The amount outstanding under this facility was \$0 and \$65,011,000 at September 30, 2016 and December 31, 2015, respectively. GWG Holdings is a performance guarantor of the various obligations of GWG Life, LLC ("GWG Life"), as servicer, under the Agreement. Obligations under the facility are secured by our pledge of ownership in our life insurance contracts to DZ Bank through an arrangement under which Wells Fargo serves as a securities intermediary.

The Agreement has certain financial (as described below) and non-financial covenants, and we were in compliance with these covenants at September 30, 2016 and December 31, 2015.

We have agreed to maintain (i) a positive consolidated net income on a non-GAAP basis (as defined and calculated under the Agreement) for each complete fiscal year, (ii) a tangible net worth on a non-GAAP basis (again, as defined and calculated under the Agreement) of not less than \$45 million, and (iii) maintain cash and eligible investments of \$15 million or above. Consolidated non-GAAP net income and non-GAAP tangible net worth as of and for the four quarters ended September 30, 2016, as calculated under the Agreement, was \$33,877,000 and \$149,361,000, respectively.

Total funds available for additional borrowings under the facility at December 31, 2015, was \$39,989,000. At September 30, 2016, the amount outstanding was \$0 and there were no policies pledged to the facility.

(6) Credit Facility — LNV Corporation

On September 14, 2016, we entered into a senior secured term loan with LNV Corporation ("LNV") as lender through our subsidiary GWG DLP Funding IV, LLC ("DLP IV") as borrower. The facility is governed by a Loan and Security Agreement (the "Loan Agreement"), with CLMG Corp. ("CLMG") acting as administrative agent on behalf of the lender under the Loan Agreement. The Loan Agreement makes available a total of up to \$172,300,000 in credit with a maturity date of September 14, 2026. Additional quarterly advances are available under the Loan Agreement. Interest will accrue on amounts borrowed under the agreement at an annual interest rate, determined as of each date of borrowing, equal to (A) the greater of 12-month LIBOR or the federal funds rate (as defined in the agreement) plus one-half of one percent per annum, plus (B) 5.75% per annum. Interest payments are made on a quarterly basis.

At September 30, 2016, the amount outstanding under this facility was \$71,250,000 and total funds available for additional borrowing, net of required reserve, was \$76,629,000.

Obligations under the facility are secured by a security interest in DLP IV's assets, for the benefit of the lenders under the Loan Agreement, through an arrangement under which Wells Fargo serves as security intermediary.

The Loan Agreement requires DLP IV to maintain a reserve account in an amount sufficient to pay 12 months of servicing, administrative and third party expenses identified under the Loan Agreement, and 12 months of debt service as calculated under the Loan Agreement. As of November 10, 2016, the amount set aside in the reserve account is \$27,500,000.

The Agreement has no financial covenants and certain non-financial reporting covenants, and we were in compliance with these covenants at September 30, 2016.

(7) Series I Secured Notes

Series I Secured Notes ("Notes") are legal obligations of GWG Life and were privately offered and sold from August 2009 through June 2011. The Notes are secured by the assets of GWG Life and are subordinate to obligations under our senior credit facilities (see Notes 5 and 6). We are party to a Third Amended and Restated Note Issuance and Security Agreement dated November 1, 2011, as amended, under which GWG Life is obligor, GWG Holdings is guarantor, and Lord Securities Corporation serves as trustee of the GWG Life Trust ("Trust"). This agreement contains certain financial and non-financial covenants, and we were in compliance with these covenants at September 30, 2016 and December 31, 2015.

The Notes were sold with original maturity dates ranging from six months to seven years, and with fixed interest rates varying from 5.65% to 9.55% depending on the term of the Note. The Notes have renewal features under which we may elect to permit their renewal, subject to the right of bondholders to elect to receive payment at maturity. Effective September 1, 2016, we no longer anticipate renewing the Notes.

Interest on the Notes is payable monthly, quarterly, annually or at maturity depending on the election of the investor. At September 30, 2016 and December 31, 2015, the weighted-average interest rate of our Notes was 8.63% and 8.47%, respectively. The principal amount of Notes outstanding was \$17,830,000 and \$23,578,000 at September 30, 2016 and December 31, 2015, respectively. The difference between the amount outstanding on the Notes and the carrying amount on our balance sheet is due to netting of unamortized deferred issuance costs. Overall, interest expense includes amortization of deferred financing and issuance costs of \$82,000 and \$275,000 for the three and nine months ended September 30, 2016 and \$49,000 and \$260,000 for the three and nine months ended September 30,

2015. Future expected amortization of deferred financing costs is \$277,000 in total over the next six years.

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(7) Series I Secured Notes (cont.)

Future contractual maturities of Notes payable and future amortization of their deferred financing costs at September 30, 2016 are as follows:

			Amo	ortization		
	Cont	ractual	of D	eferred		
Years Ending December 31,	Maturities			Financing Costs		
Three months ending December 31, 2016	\$	1,177,000	\$	5,000		
2017		10,522,000		88,000		
2018		2,401,000		49,000		
2019		1,023,000		22,000		
2020		1,766,000		55,000		
Thereafter		941,000		58,000		
	\$	17,830,000	\$	277,000		

(8) L Bonds

Our L Bonds are legal obligations of GWG Holdings. Obligations under the L Bonds are secured by the assets of GWG Holdings and by GWG Life, as a guarantor, and are subordinate to the obligations under our senior credit facilities (see Notes 5 and 6). We began publicly offering and selling L Bonds in January 2012 under the name "Renewable Secured Debentures." These debt securities were re-named "L Bonds" in January 2015. L Bonds are publicly offered and sold on a continuous basis under a registration statement permitting us to sell up to \$1.0 billion in principal amount of L Bonds. We are party to an indenture governing the L Bonds dated October 19, 2011, as amended ("Indenture"), under which GWG Holdings is obligor, GWG Life is guarantor, and Bank of Utah serves as indenture trustee. The Indenture contains certain financial and non-financial covenants, and we were in compliance with these covenants at September 30, 2016 and December 31, 2015.

Effective September 1, 2016, we discontinued the sales of 6-month and 1-year L Bonds. In addition, effective September 1, 2016, the L Bond interest rates changed to 5.50%, 6.25%, 7.50% and 8.50% for the 2-, 3-, 5- and 7-year L Bonds, respectively. The bonds have renewal features under which we may elect to permit their renewal, subject to the right of bondholders to elect to receive payment at maturity. Interest is payable monthly or annually depending on the election of the investor.

At September 30, 2016 and December 31, 2015, the weighted-average interest rate of our L Bonds was 7.16% and 7.18%, respectively. The principal amount of L Bonds outstanding was \$384,586,000 and \$282,171,000 at September 30, 2016 and December 31, 2015, respectively. The difference between the amount of outstanding L Bonds and the carrying amount on our balance sheets is due to netting of unamortized deferred issuance costs and cash receipts for new issuances in process. Amortization of deferred issuance costs was \$2,073,000 and \$5,362,000 for the three and nine months ended September 30, 2016 and \$1,892,000 and \$4,232,000 for the three and nine months ended September 30, 2015. Future expected amortization of deferred financing costs as of September 30, 2016 is \$11,622,000 in total over the next eight years.

Future contractual maturities of L Bonds, and future amortization of their deferred financing costs, at September 30, 2016 are as follows:

Years Ending December 31,	Contractual	Amortization
	Maturities	of Deferred

		Financing Costs		
Three months ending December 31, 2016	\$ 23,548,000	\$	115,000	
2017	112,987,000		1,708,000	
2018	101,130,000		3,106,000	
2019	78,098,000		3,222,000	
2020	19,291,000		784,000	
Thereafter	49,532,000		2,687,000	
	\$ 384,586,000	\$	11,622,000	
F-13				
2019 2020 Thereafter	\$ 78,098,000 19,291,000 49,532,000	\$	3,222,000 784,000 2,687,000	

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(9) Convertible Preferred Stock

From July 2011 until September 2012, we privately offered shares of Series A Preferred Stock ("Series A") of GWG Holdings at \$7.50 per share. In the offering, we sold an aggregate of 3,278,000 shares for gross consideration of \$24,582,000. Holders of Series A are entitled to cumulative dividends at the rate of 10% per annum, paid quarterly. Dividends on the Series A are included as interest expense in the statements of operations. Under certain circumstances described in the Certificate of Designation for the Series A, additional Series A shares may be issued in lieu of cash dividends at the rate of \$7.00 per share.

Holders of Series A are entitled to a liquidation preference equal to the stated value of their preferred shares (i.e., \$7.50 per share) plus accrued but unpaid dividends. Holders of Series A may presently convert each share of their Series A into 0.75 shares of our common stock at the rate of \$10.00 per share.

As of September 30, 2016, we issued an aggregate of 447,000 shares of Series A in satisfaction of \$3,129,000 in dividends on the Series A, and an aggregate of 696,000 shares of Series A were converted into 522,000 shares of our common stock. As of September 30, 2016, we had 2,650,000 Series A shares outstanding with respect to which we incurred aggregate issuance costs of \$2,838,000, all of which is included as a component of additional paid-in capital.

Purchasers of Series A in our offering received warrants to purchase an aggregate of 431,954 shares of our common stock at an exercise price of \$12.50 per share. The grant date fair value of these warrants was \$428,000. As of September 30, 2016 and December 31, 2015, none of these warrants were exercised, and the weighted-average remaining life of these warrants was 0.68 and 1.43 years, respectively.

In September 2012, we completed a public offering of our common stock and, as a result, the Series A was reclassified from temporary equity to permanent equity. We may redeem Series A shares under the Certificate of Designation at a price equal to 110% of their liquidation preference (\$7.50 per share) at any time. As of September 30, 2016, we have redeemed an aggregate of 277,000 shares of Series A.

(10) Redeemable Preferred Stock

Beginning November 30, 2015, we began publicly offering up to 100,000 shares of Redeemable Preferred Stock ("RPS") at \$1,000 per share. Holders of RPS are entitled to cumulative dividends at the rate of 7% per annum, paid monthly. Dividends on the RPS are included as interest expense in the statements of operations. Under certain circumstances described in the Certificate of Designation for the RPS, additional shares of RPS may be issued in lieu of cash dividends.

The RPS ranks senior to our common stock and pari passu with our Series A, and entitles its holders to a liquidation preference equal to the stated value per share (i.e., \$1,000) plus accrued but unpaid dividends. Holders of RPS may presently convert their RPS into our common stock at a conversion price equal to the volume-weighted average price of our common stock for the 20 trading days immediately prior to the date of conversion, subject to a minimum conversion price of \$15.00 and in an aggregate amount limited to 15% of the stated value of RPS originally purchased by such holder from us and still held by such holder.

Holders of RPS may request that we redeem their RPS at a price equal to their liquidation preference at a price equal to their stated value plus accrued but unpaid dividends, less an applicable redemption fee, if any. Nevertheless, the Certificate of Designation for RPS permits us to decline requests for redemption in certain circumstances. Subject to certain restrictions and conditions, we may also redeem shares of RPS without a redemption fee upon a holder's death,

total disability or bankruptcy. In addition, after one year from the date of original issuance, we may, at our option, call and redeem shares of RPS at a price equal to their liquidation preference.

As of September 30, 2016, we had sold 33,201 shares of RPS for aggregate gross consideration of \$33,177,000, and incurred approximately \$2,399,000 of selling costs related to the sale of those shares.

(11) GWG MCA Capital, Inc — 9% Preferred Stock

Beginning March 31, 2016, GWG MCA began privately offering up to 2,000,000 shares of GWG MCA 9% Preferred Stock ("MCA Preferred") at \$10.00 per share. Holders of MCA Preferred are entitled to cumulative dividends at a rate of 9% per annum, paid monthly. Dividends on the MCA Preferred are included as interest expense in the statements of operations. As of September 30, 2016, a total of 7,155 shares of MCA Preferred had been sold for aggregate gross consideration of \$72,000 and approximately \$7,000 of selling costs related to the sale of these shares were incurred.

Holders of MCA Preferred were redeemed as of September 30, 2016 at the stated value of their shares plus accrued but unpaid dividends.

(12) Income Taxes

We had a current income tax liability of \$0 as of both September 30, 2016 and December 31, 2015. The components of current and deferred income tax expense for the three and nine months ended September 30, 2016 and 2015, respectfully, consisted of the following:

	Th	ree Months E	Ended				Nin	e Months Ended			
	Se	ptember 30,		Se	ptember 30,		Sep	tember 30,	Se	ptember 30,	
	20	16		20	15		201	6	20	15	
Income tax provision											
(benefit):											
Current:											
Federal	\$			\$	(141,000)	\$		\$	_	
State	\$			\$	(40,000)	\$		\$	_	
Total current tax expense											
(benefit)					(181,000)				_	
Deferred:											
Federal	\$	(1,082,000)	\$	(1,488,000)	\$	1,121,000	\$	(504,000)
State	\$	(346,000)	\$	(429,000)	\$	358,000	\$	(161,000)
Total deferred tax expense											
(benefit)		(1,428,000)		(1,917,000)		1,479,000		(665,000)
Total income tax expense											
(benefit)		(1,428,000)		(2,098,000)		1,479,000		(665,000)

We provided a valuation allowance against the deferred tax asset related to a note receivable, which was charged-off for financial reporting purposes, because we believe that, when realized for tax purposes, it will result in a capital loss that will not be utilized because we have no expectation of generating a capital gain within the applicable carryforward period. Therefore, we do not believe that it is "more likely than not" that the deferred tax asset will be realized.

We also provided a valuation allowance against the deferred tax asset related to a tax basis capital loss generated with respect to our settlement and subsequent disposal of an earlier investment in Athena Structured Funds PLC. As we have no expectation of generating capital gains with the applicable carryforward period, we do not believe that it is "more likely than not" that the deferred asset will be realized.

The primary differences between the September 30, 2016 effective tax rate and the statutory federal rate are the accrual of non-deductible preferred stock dividend expense of \$2,153,000, state taxes, and other non-deductible

expenses. The most significant temporary differences between GAAP net income and taxable net income are the treatment of interest costs with respect to the acquisition of the life insurance contracts and revenue recognition with respect to the mark-to-market of our life insurance portfolio.

(13) Common Stock

In September 2014, we consummated an initial public offering of our common stock resulting in the sale of 800,000 shares of common stock at \$12.50 per share, and net proceeds of approximately \$8.6 million after the payment of underwriting commissions, discounts and expense reimbursements. In connection with this offering, we listed our common stock on the Nasdaq Capital Market under the ticker symbol "GWGH."

On June 24, 2015 we issued 60,000 restricted common shares at \$9.70 per share, determined by the closing market price on the date of grant, to a vendor as payment for services to be rendered over three years. The cost of these shares is amortized over a 12-month period. On March 17, 2016, we issued an additional 6,500 restricted common shares at an average price of \$7.16 per share, determined by the closing market price on the date of grant, to this same vendor for additional services provided to us. On April 25, 2016, we issued 25,000 restricted shares of common stock at \$6.25 per share, determined by the closing market price on the date of grant, to a vendor as a form of payment for services the vendor is providing to us, which is expensed in the current period.

(14) Stock Incentive Plan

We adopted our GWG Holdings 2013 Stock Incentive Plan in March 2013. The Compensation Committee of our Board of Directors administers the plan. Incentives under the plan may be granted incentive stock options and non-statutory stock options; stock appreciation rights; stock awards; restricted stock; restricted stock units; and performance shares. Eligible participants include officers and employees of GWG Holdings and its subsidiaries, members of our Board of Directors, and consultants. 2,000,000 common shares are presently issuable under the plan.

Stock Options — Through September 30, 2016, we issued stock options for 1,237,000 shares of common stock to employees, officers, and directors under the plan. Options for 687,000 shares have vested, and the remaining options are scheduled to vest over three years. The options were issued with an exercise price between \$6.35 and \$10.18 for those beneficially owning more than 10% of our common stock, and between \$6.00 and \$10.25 for all others, which is equal to the estimated market price of the shares on the date of grant using Black-Scholes binomial option pricing model. The expected annualized volatility used in the Black-Scholes model valuation of options issued during the period was 25.5%. The annual volatility rate is based on the standard deviation of the average continuously compounded rate of return of five selected comparable companies over the previous 52 weeks. A forfeiture rate of 15% is based on historical information and expected future trend. As of September 30, 2016, stock options for 415,000 shares were forfeited and stock options for 28,000 shares were exercised.

Outstanding stock options:

	Vested	Un-vested		Total	
Balance as of December 31, 2014	314,288	685,813		1,000,101	
Granted during the year	79,500	273,700		353,200	
Vested during the year	238,999	(238,999)	_	
Exercised during the year	(27,667)	_		(27,667)
Forfeited during the year	(121,417)	(150,602)	(272,019)
Balance as of December 31, 2015	483,703	569,912		1,053,615	
Granted during the year	22,500	239,948		262,448	
Vested during the year	187,473	(187,473)		
Forfeited during the year	(6,676)	(72,824)	(79,500)
Balance as of September 30, 2016	687,000	549,563		1,236,563	

Compensation expense related to un-vested options not yet recognized is \$420,000. We expect to recognize this compensation expense over the next three years (\$14,000 in 2016, \$240,000 in 2017, \$109,000 in 2018, and \$57,000 in 2019).

(14) Stock Incentive Plan (cont.)

Stock Appreciation Rights (SARs) — On September 19, 2016 we issued SARs for 145,388 shares of the common stock to employees. The strike price of the SARs was \$8.76, which was equal to the market price of the common stock at the close of business on September 19, 2016. 56,358 of the SARs were vested as of September 30, 2016, on which date the market price of the common stock was \$8.82. A forfeiture rate of 15% was used in calculating our liability for the SARs.

Outstanding Stock Appreciation Rights:

	Vested	Un-vested	Total
Balance as of December 31, 2015	_	_	
Granted during the year	56,358	89,030	145,388
Vested during the year	56,358	89,030	145,388
Forfeited during the year	_		
Balance as of September 30, 2016	56,358	89,030	145,388

A liability for Stock Appreciation Rights - Compensation Expense was recorded on September 30, 2016 in the amount of \$3,381 and Compensation Expense was charged for the same amount.

(15) Net Income per Common Share

We have outstanding Series A, as described in Note 9. The Series A are dilutive to our net income per common share calculation for the nine-month period ended September 30, 2016. They are anti-dilutive for the three-month period ended September 30, 2016 and for both three and nine-month periods ended September 30, 2015. We also issued warrants to purchase common stock in conjunction with the sale of Series A (see Note 9). Both those warrants and our vested stock options are anti-dilutive for both three and nine-month periods ended September 30, 2016 and 2015 and have not been included in the fully diluted net loss per common share calculation. We issued RPS (see Note 10). The RPS is dilutive for the nine-month period ended September 30, 2016 and anti-dilutive for the three-month period ended September 30, 2016.

(16) Commitments

We are party to an office lease with U.S. Bank National Association as the landlord. On September 1, 2015, we entered into an amendment to our original lease that expanded the leased space to 17,687 square feet and extended the term through August 31, 2025. Under the amended lease, we are obligated to pay base rent plus common area maintenance and a share of building operating costs. Rent expenses under these lease arrangements were \$102,000 and \$71,000 for the three months ended September 30, 2016 and 2015, respectively, and \$306,000 and \$193,000 for the nine months ended September 30, 2016 and 2015, respectively.

Minimum lease payments under the amended lease are as follows:

Three months ending December 31, 2016	\$ 44,000
2017	178,000
2018	185,000
2019	191,000
2020	198,000
2021	204,000

2022	210,000
2023	217,000
2024	223,000
2025	230,000
2026	38,000
	\$ 1,918,000
F-17	

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(17) Contingencies

Litigation — In the normal course of business, we are involved in various legal proceedings. In the opinion of management, any liability resulting from such proceedings would not have a material adverse effect on our financial position, results of operations or cash flows.

(18) Guarantee of L Bonds

We are publicly offering and selling L Bond under a registration statement declared effective by the SEC, as described in Note 8. Our obligations under the L Bonds are secured by substantially all the assets of GWG Holdings, a pledge of all the common stock held individually by our largest stockholders, and by a guarantee and corresponding grant of a security interest in substantially all the assets of GWG Life. As a guarantor, GWG Life has fully and unconditionally guaranteed the payment of principal and interest on the L Bonds. Substantially all of GWG's life insurance contracts are held by wholly owned subsidiaries of GWG Life: DLP III, DLP IV and the Trust. GWG Life's equity ownership in these subsidiaries serves as collateral for the L Bond obligation. The life insurance contracts held by DLP III and DLP IV are not direct collateral for the L Bond obligations but do serve as direct collateral for the senior credit facilities.

The consolidating financial statements are presented in lieu of separate financial statements and other related disclosures of the subsidiary guarantor and issuer because management does not believe that separate financial statements and related disclosures would be material to investors. There are currently no significant restrictions on the ability of GWG Holdings or GWG Life, the guarantor subsidiary, to obtain funds from its subsidiaries by dividend or loan, except as provided herein. A majority of insurance contracts we own are subject to a collateral arrangement with LNV described in Note 6. Under this arrangement, collection and escrow accounts are used to fund premiums for the insurance contracts and to pay interest and other charges under the senior credit facility.

The following represents consolidating financial information as of September 30, 2016 and December 31, 2015, with respect to the financial position, and for the three and nine months ended September 30, 2016 and 2015, with respect to results of operations and cash flows of GWG Holdings and its subsidiaries. The parent column presents the financial information of GWG Holdings, the primary obligor for the L Bonds. The guarantor subsidiary column presents the financial information of GWG Life, the guarantor subsidiary of the L Bonds, presenting its investment in DLP III, DLP IV and the Trust under the equity method. The non-guarantor subsidiaries column presents the financial information of all non-guarantor subsidiaries, including DLP III, DLP IV and the Trust.

(18) Guarantee of L Bonds (cont.)

Condensed Consolidating Balance Sheets

September 30, 2016	Parent	Guarantor Subsidiary <u>ASSI</u>	Non-Guarantor Subsidiaries ETS	Eliminations	Consolidated
Cash and cash equivalents Restricted cash Investment in life	\$ 13,312,751 —	\$ 4,372,845 4,438,025	\$ 1,088,232 11,250,000	\$ <u> </u>	\$ 18,773,828 15,688,025
insurance contracts, at fair value Secured MCA	_	_	477,585,100	_	477,585,100
advances Life insurance	_	_	6,113,831	_	6,113,831
contract benefits receivable Other assets Investment in		 1,224,386	6,129,022 54,726	<u>(2,854,126</u>)	6,129,022 3,131,107
subsidiaries	422,185,881	429,441,035	_	(851,626,916)	_
TOTAL ASSETS	\$ 440,204,753	\$ 439,476,291	\$ 502,220,911	\$ (854,481,042)	\$ 527,420,913
	<u>LIABILITI</u>	ES & STOCKHOL	DERS' EQUITY	(DEFICIT)	
LIABILITIES Senior credit					
facilities Series I Secured	\$ —	\$ —	\$ 63,699,385	\$ —	\$ 63,699,385
Notes L Bonds Notes payable to	— 379,858,737	17,553,307 —			17,553,307 379,858,737
related parties Accounts payable Interest payable		99,705 3,588,954	2,700,000 1,643,237 400,077	(2,700,000) — (154,126)	
Other accrued	259,722 3,242,586	351,896 —	33,725		645,343 3,242,586
TOTAL LIABILITIES	393,859,287	21,593,862	68,476,424	(2,854,126)	481,075,447
STOCKHOLDERS' EQUITY (DEFICIT)					
Member capital	<u> </u>	417,882,429	433,744,487	(851,626,916)	

Convertible					
preferred stock					
Redeemable					
preferred stock	33,176,600	_	_	_	33,176,600
Common stock	5,980	_	_	_	5,980
Additional paid-in					
capital	15,226,449	_	_	_	15,226,449
Accumulated deficit	(21,836,494)	_	_	_	(21,836,494)
TOTAL					
STOCKHOLDERS'					
EQUITY (DEFICIT)	46,345,466	417,882,429	433,744,487	(851,626,916)	46,345,466
TOTAL					
LIABILITIES AND					
STOCKHOLDERS'					
EQUITY (DEFICIT)	\$ 440,204,753	\$ 439,476,291	\$ 502,220,911	\$ (854,481,042)	\$ 527,420,913
F-19					

(18) Guarantee of L Bonds (cont.)

Condensed Consolidating Balance Sheets (continued)

December 31, 2015	Parent	Guarantor Subsidiary <u>ASSE</u>	Non-Guarantor Subsidiaries TS	Eliminations	Consolidated
Cash and cash equivalents Restricted cash Investment in life	\$ 32,292,162 —	\$ 1,982,722 2,102,257	\$ 150,221 239,643	\$ <u> </u>	\$ 34,425,105 2,341,900
insurance contracts, at fair value Other assets Investment in	 1,742,074	 688,071	356,649,715 30,900		356,649,715 2,461,045
subsidiaries	269,886,254	291,295,951	_	(561,182,205)	_
TOTAL ASSETS	\$ 303,920,490	\$ 296,069,001	\$ 357,070,479	\$ (561,182,205)	\$ 395,877,765
	<u>LIABILITI</u>	ES & STOCKHOL	DERS' EQUITY	(DEFICIT)	
LIABILITIES Senior credit					
facilities Series I Secured	\$ —	\$ (1,000,000)	\$ 64,279,596	\$ —	\$ 63,279,596
Notes L Bonds Accounts payable Interest payable	— 276,482,796 280,988 8,529,959	23,287,704 — 157,217 3,544,626		_ _ _ _	23,287,704 276,482,796 1,517,440 12,340,061
Other accrued expenses Deferred taxes, net TOTAL	717,365 1,763,968	343,421			1,060,786 1,763,968
LIABILITIES	287,775,076	26,332,968	65,624,307	_	379,732,351
STOCKHOLDERS' EQUITY (DEFICIT)					
Member capital Convertible	_	269,736,033	291,446,172	(561,182,205)	
preferred stock Common stock	20,784,841 5,942			_ _	20,784,841 5,942
Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS'	17,149,391 (21,794,760) 16,145,414				17,149,391 (21,794,760) 16,145,414

)

EQUITY (DEFICIT)

TOTAL
LIABILITIES AND
STOCKHOLDERS'
EQUITY (DEFICIT) \$ 303,920,490 \$ 296,069,001 \$ 357,070,479 \$ (561,182,205) \$ 395,877,765
F-20

(18) Guarantee of L Bonds (cont.)

Condensed Consolidating Statements of Operations

For the nine months ended September 30, 2016 REVENUE	Parent		Guarantor Subsidiary	G	on- uarantor ubsidiaries	Eliminations		Consolidated
Origination and servicing income Gain on life insurance	\$ —	\$	\$ 13,417	\$	_	\$ (13,417)	\$ —
contracts, net MCA income Interest and other			_		51,606,815 654,441	_		51,606,815 654,441
income TOTAL REVENUE	181,828 181,828		31,137 44,554		282,259 52,543,515	(154,126 (167,543)	341,098 52,602,354
EXPENSES Origination and servicing fees Interest expense Employee		20	 1,856,909		13,417 4,829,831	(13,417 (154,126)	 32,009,934
compensation and benefits Legal and professional	4,894,00	6	3,151,107		405,055	_		8,450,168
fees Other expenses TOTAL EXPENSES	1,642,25 4,241,82 36,255,4	5	1,308,959 2,197,133 8,514,108		146,101 1,169,099 6,563,503	 (167,543)	3,097,312 7,608,057 51,165,471
INCOME (LOSS) BEFORE EQUITY IN INCOME OF								
SUBSIDIARIES	(36,073,	575)	(8,469,554)		45,980,012			1,436,883
EQUITY IN INCOME OF SUBSIDIARY	37,510,4	58	46,497,731		_	(84,008,18	9)	_
INCOME BEFORE INCOME TAXES	1,436,88	3	38,028,177		45,980,012	(84,008,18	9)	1,436,883
INCOME TAX EXPENSE NET INCOME	1,478,61	7	_		_	_		1,478,617
(LOSS) F-21	\$ (41,734) \$	38,028,177	\$	45,980,012	\$ (84,008,18	9)	\$ (41,734)

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(18) Guarantee of L Bonds (cont.)

Condensed Consolidating Statements of Operations (continued)

For the nine months ended September 30, 2015 REVENUE	Parent	Guarantor Subsidiary	Non- Guarantor Subsidiaries	Eliminations	Consolidated
Origination and servicing income Gain on life	\$ —	\$ 2,022,774	\$ —	\$ (2,022,774)	\$ —
settlements, net Interest and other	_	_	33,446,556	_	33,446,556
income TOTAL REVENUE	38,944 38,944	61,694 2,084,468	132,878 33,579,434	<u>(2,022,774</u>)	233,516 33,680,072
EXPENSES Origination and					
servicing fees Interest expense Employee	— 18,011,890	1,984,356	2,022,774 3,152,784	(2,022,774)	23,149,030
compensation and benefits Legal and professional	4,671,183	1,509,703	_	_	6,180,886
fees Other expenses	1,427,388 3,251,606	560,873 2,297,063	— 97,733		1,988,261 5,646,402
TOTAL EXPENSES	27,362,067	6,351,995	5,273,291	(2,022,774)	36,964,579
INCOME (LOSS) BEFORE EQUITY IN INCOME OF					
SUBSIDIARIES	(27,323,123	3) (4,267,527)	28,306,143	_	(3,284,507)
EQUITY IN INCOME OF SUBSIDIARY	24,038,616	28,305,979	_	(52,344,595)	_
NET INCOME (LOSS) BEFORE INCOME TAXES	(3,284,507) 24,038,452	28,306,143	(52,344,595)	(3,284,507)
INCOME TAX BENEFIT NET INCOME	(664,905) —	_	_	(664,905)
(LOSS) F-22	\$ (2,619,602) \$ 24,038,452	\$ 28,306,143	\$ (52,344,595)	\$ (2,619,602)

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(18) Guarantee of L Bonds (cont.)

Condensed Consolidating Statements of Operations (continued)

For the three months ended September 30, 2016 REVENUE	Pa	arent	uarantor ubsidiary	G	on- uarantor ıbsidiaries	Е	liminations		C	onsolidated
Gain on life insurance										
contracts, net		_			13,509,755		_			13,509,755
MCA income		_	_		286,225		_			286,225
Interest and other										
income		75,808	30,126		83,313		(64,249)		124,998
TOTAL REVENUE		75,808	30,126		13,879,293		(64,249)		13,920,978
EXPENSES										
Interest expense		9,747,128	554,938		1,746,151		(64,249)		11,983,968
Employee		<i>></i> ,, , , 120	33 1,730		1,7 10,121		(0.,2.)	,		11,505,500
compensation and										
benefits		1,718,683	1,038,058		155,722					2,912,463
Legal and professional		,	, ,		•					
fees		263,917	297,804		25,109		_			586,830
Other expenses		1,464,498	803,106		595,608					2,863,212
TOTAL EXPENSES		13,194,226	2,693,906		2,522,590		(64,249)		18,346,473
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES		/12 110 410 N	(2.662.790.)		11 256 702					(4.425.405.)
SUDSIDIARIES		(13,118,418)	(2,663,780)		11,356,703		_			(4,425,495)
EQUITY IN INCOME OF SUBSIDIARY		8,692,923	11,361,329		_		(20,054,252	2)		_
INCOME (LOSS) BEFORE INCOME TAXES		(4,425,495)	8,697,549		11,356,703		(20,054,252	2)		(4,425,495)
INCOME TAX BENEFIT NET INCOME		(1,418,130)	_		_		_			(1,428,130)
(LOSS) F-23	\$	(2,997,365)	\$ 8,697,549	\$	11,356,703	\$	(20,054,252	2)	\$	(2,997,365)

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(18) Guarantee of L Bonds (cont.)

Condensed Consolidating Statements of Operations (continued)

For the three months ended September 30, 2015 REVENUE	Parent	Guarantor Subsidiary	Non- Guarantor Subsidiaries	Eliminations	Consolidated
Origination and servicing income Gain on life	\$ —	\$ 1,004,024	\$ —	\$ (1,004,024)	\$ —
settlements, net Interest and other	_	_	8,189,261	_	8,189,261
income	13,922	54,813	25,106		93,841
TOTAL REVENUE	13,922	1,058,837	8,214,367	(1,004,024)	8,283,102
EXPENSES Origination and					
servicing fees		_	1,004,024	(1,004,024)	
Interest expense	6,980,132	525,391	1,144,626	_	8,650,149
Employee compensation and	-,,-		, ,-		-,,
benefits	1,759,589	548,657	_	_	2,308,246
Legal and professional					
fees	598,530	223,547			822,077
Other expenses	1,195,417	995,026	40,898		2,231,341
TOTAL EXPENSES	10,533,668	2,292,621	2,189,548	(1,004,024)	14,011,813
INCOME (LOSS) BEFORE EQUITY IN INCOME OF					
SUBSIDIARIES	(10,519,746)	(1,233,784)	6,024,819	_	(5,728,711)
EQUITY IN INCOME OF SUBSIDIARY	4,791,035	6,024,762	_	(10,815,797)	_
NET INCOME (LOSS) BEFORE INCOME	(5 700 711)	4 700 079	6.024.910	(10.915.707.)	(5 720 711)
TAXES	(5,728,711)	4,790,978	6,024,819	(10,815,797)	(5,728,711)
INCOME TAX BENEFIT NET INCOME (LOSS) F-24	(2,097,633) \$ (3,631,078)	— \$ 4,790,978	 \$ 6,024,819	_ \$ (10,815,797)	(2,097,633) \$ (3,631,078)

(18) Guarantee of L Bonds (cont.)

Condensed Consolidating Statements of Cash Flows

For the nine months ended September 30, 2016 CASH FLOWS FROM OPERATING ACTIVITIES	Parent	Guarantor Subsidiary	Non- Guarantor Subsidiaries	Eliminations	Consolidated
Net income Adjustments to reconcile net income to net cash flows from operating activities:	\$ (41,734)	\$ 38,028,177	\$ 45,980,012	\$ (84,008,189)	\$ (41,734)
(Equity) of subsidiaries Gain on life insurance	(37,510,459)	(46,497,730)	_	84,008,189	_
contracts Amortization of deferred financing and issuance	_	_	(53,846,155)	_	(53,846,155)
costs Deferred income taxes Preferred stock	5,982,802 1,478,617	(1,364,614)	1,459,717 —	_	6,077,905 1,478,617
dividends payable (Increase) in operating assets:	663,614	_	_	_	663,614
Life insurance contract benefits receivable Other assets Increase (decrease) in operating liabilities:	— (114,885,990)	— (92,168,163)	(6,129,022)	206,436,523	(6,129,022) (617,630)
Due to related party Accounts payable and	(2,867,225)	(15,505)	2,700,000	_	(182,730)
accrued expenses NET CASH FLOWS USED IN OPERATING	2,396,503	2,889,525	(7,310,262)	_	(2,024,234)
ACTIVITIES	(144,783,872)	(99,128,310)	(17,145,710)	206,436,523	(54,621,369)
CASH FLOWS FROM INVESTING ACTIVITIES Investment in life					
insurance contracts Carrying value of matured life insurance	_	_	(74,470,362)	_	(74,470,362)
contracts	<u> </u>	_	7,381,132 (7,613,310)	<u> </u>	7,381,132 (7,613,310)

Investment in Secured MCA advances					
Proceeds from Secured MCA advances NET CASH FLOWS	_	_	1,246,703	_	1,246,703
USED IN INVESTING ACTIVITIES	_	_	(73,455,837)	_	(73,455,837)
CASH FLOWS FROM FINANCING ACTIVITIES					
Net borrowings on Senior Credit Facilities Payments for redemption of Series I	_	_	6,238,952	_	6,238,952
Secured Notes Proceeds from issuance	_	(6,264,018)	_	_	(6,264,018)
of L Bonds Payments for	135,477,090	_	_	_	135,477,090
redemption and issuance of L Bonds Proceeds from (increase	(37,036,922)	_	_	_	(37,036,922)
in) restricted cash Issuance of common	_	(2,335,768)	(11,010,358)	_	(13,346,126)
stock	244,185	_	_	_	244,185
Proceeds from issuance of preferred stock Payments for issuance	31,215,986	_	71,555	_	31,287,541
and redemption of preferred stock Issuance of member	(4,095,878)		(78,895)	_	(4,174,773)
capital NET CASH FLOWS PROVIDED BY	_	110,118,219	96,318,304	(206,436,523)	_
FINANCING ACTIVITIES	125,804,461	101,518,433	91,539,558	(206,436,523)	112,425,929
NET INCREASE (DECREASE) IN CASH AND CASH					
EQUIVALENTS	(18,979,411)	2,390,123	938,011	_	(15,651,277)
CASH AND CASH EQUIVALENTS BEGINNING OF THE					
PERIOD	32,292,162	1,982,722	150,221	_	34,425,105
END OF THE PERIOD F-25	\$ 13,312,751	\$ 4,372,845	\$ 1,088,232	\$ —	\$ 18,773,828

(18) Guarantee of L Bonds (cont.)

Consolidating Statements of Cash Flows (continued)

For the nine months ended September 30, 2015	Parent	Guarantor Subsidiary	Non- Guarantor Subsidiaries	Eliminations	Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net income to net cash flows from	\$(2,619,602)	\$24,038,452	\$28,306,143	\$(52,344,595)	\$(2,619,602)
operating activities: (Equity) of subsidiaries Gain on life settlements Amortization of deferred financing	(24,038,617)	(28,305,978)	<u>(26,651,363)</u>	52,344,595 —	— (26,651,363)
and issuance costs Deferred income taxes	2,832,487 (664,905)	260,455 —	(1,201,170)	_	1,891,772 (664,905)
Convertible, redeemable preferred dividends payable (Increase) decrease in operating	509,225	_	_	_	509,225
assets: Policy benefits receivable Other assets Increase (decrease) in operating liabilities:	— (40,145,769)	— (26,745,888)	1,392,986	66,117,118	1,392,986 (774,539)
Accounts payable and accrued expenses NET CASH FLOWS USED IN OPERATING ACTIVITIES	4,503,624 (30,425,246)	123,222 (30,629,737)	(790,131) 1,056,465	— 66,117,118	3,836,715 (23,079,711)
CASH FLOWS FROM INVESTING ACTIVITIES					
Investment in life settlements Carrying value of matured life	_	_	(23,850,860)	_	(23,850,860)
insurance contracts NET CASH FLOWS USED IN	_	_	3,822,983	_	3,822,983
INVESTING ACTIVITIES	_	_	(20,027,877)	_	(20,027,877)
CASH FLOWS FROM FINANCING ACTIVITIES Repayment of senior credit					
facilities Payments for redemption of Series	_	_	(7,150,000)	_	(7,150,000)
I Secured Notes Proceeds from issuance of L Bonds	— 87,620,483 (32,376,104)	(4,508,130) — —	_ _ _	_ _ _	(4,508,130) 87,620,483 (32,376,104)

Payments for redemption and					
issuance of L Bonds		(2.20(.200.)	(660.207		(2.075.507.)
Payments from restricted cash		(2,306,300)	(669,207)		(2,975,507)
Issuance of common stock	582,000				582,000
Payments for redemption preferred	(205 105				(205 105
stock	(295,185)		— 26 040 702	— (66 117 110)	(295,185)
Issuance of member capital	_	39,176,335	26,940,783	(66,117,118)	
NET CASH FLOWS PROVIDED	<i>55 5</i> 21 10 <i>4</i>	22 261 005	10 101 576	(((117 110)	40 007 557
BY FINANCING ACTIVITIES	55,531,194	32,361,905	19,121,576	(66,117,118)	40,897,557
NET INCREASE (DECREASE)					
IN CASH AND CASH					
EQUIVALENTS	(4,092,363)	1,732,168	150,164		(2,210,031)
EQUIVILLIVIS	(4,072,303)	1,732,100	150,104		(2,210,031)
CASH AND CASH					
EQUIVALENTS					
BEGINNING OF THE PERIOD	30,446,473	216,231	_		30,662,704
	20,110,170	210,201			20,002,70.
END OF THE PERIOD	\$26,354,110	\$1,948,399	\$150,164	\$ —	\$28,452,673
F-26	, ,	. ,,	, -	•	, - ,

(18) Guarantee of L Bonds (cont.)

Consolidating Statements of Cash Flows (continued)

For the three months ended September 30, 2016 CASH FLOWS FROM OPERATING	Parent	Guarantor Subsidiary	Non- Guarantor Subsidiaries	Eliminations	Consolidated
ACTIVITIES Net income Adjustments to reconcile net loss to net cash flows	\$ (2,997,365)	\$ 8,697,549	\$ 11,356,703	\$ (20,054,252)	\$ (2,997,365)
from operating activities: (Equity) of subsidiaries Gain on life insurance	(8,692,924)	(11,361,328)	_	20,054,252	_
contracts Amortization of deferred	_	_	(21,073,226)	_	(21,073,226)
financing and issuance costs Deferred income taxes	2,072,879 (1,428,130)	81,849 —	611,015	_ _	2,765,743 (1,428,130)
Preferred stock dividends payable (Increase) in operating assets: Life insurance contract	333,565	_	_	_	333,565
benefits receivable Other assets Increase (decrease) in operating liabilities:	<u>(54,428,152)</u>	<u>(54,272,589)</u>	700,000 —	— 109,120,577	700,000 419,836
Due to related party Accounts payable and	(64,249)	(16,700)	_	_	(80,949)
other accrued expenses NET CASH FLOWS USED IN OPERATING	155,980	2,172,227	(5,545,197)	_	(3,216,990)
ACTIVITIES	(65,048,396)	(54,698,992)	(13,950,705)	109,120,577	(24,577,516)
CASH FLOWS FROM INVESTING ACTIVITIES Investment in life					
insurance contracts Carrying value of matured	_	_	(25,770,326)	_	(25,770,326)
life insurance contracts Investment in Secured	_	_	1,078,889	_	1,078,889
MCA advances	_ _	_ _	(1,965,896) 220,911	_	(1,965,896) 220,911

Proceeds from Secured MCA advances NET CASH FLOWS USED IN INVESTING ACTIVITIES	_	_	(26,436,422)	_	(26,436,422)
CASH FLOWS FROM FINANCING ACTIVITIES Net repayment of Senior					
Credit Facilities	_	_	(10,761,048)		(10,761,048)
Payments for redemption of Series I Secured Notes Proceeds from issuance of	_	(541,275)	_	_	(541,275)
L Bonds	64,350,430		_		64,350,430
Payments for redemption and issuance of L Bonds Proceeds from (increase in)	(14,373,447)	_	_	_	(14,373,447)
restricted cash Issuance of member capital	_	486,283 52,304,345	(5,013,515) 56,816,232	— (109,120,577)	(4,527,232)
Issuance of common stock Proceeds from issuance of	31,515		_	_	31,515
preferred stock Payments for issuance and	20,786,332	_	_	_	20,786,332
redemption of preferred stock NET CASH FLOWS PROVIDED BY	(2,485,304)	_	(71,555)	_	(2,556,859)
FINANCING ACTIVITIES	68,309,526	52,249,353	40,970,114	(109,120,577)	52,408,416
NET INCREASE IN CASH AND CASH EQUIVALENTS	3,261,130	(2,449,639)	582,987	_	1,394,478
CASH AND CASH EQUIVALENTS BEGINNING OF THE	10.051.621	6 922 494	E05 245		17.270.250
PERIOD	10,051,621	6,822,484	505,245	_	17,379,350
END OF THE PERIOD F-27	\$ 13,312,751	\$ 4,372,845	\$ 1,088,232	\$ —	\$ 18,773,828

(18) Guarantee of L Bonds (cont.)

FINANCING

Consolidating Statements of Cash Flows (continued)

For the three months ended September 30, 2015 CASH FLOWS FROM OPERATING	Parent	Guarantor Sub	Non- Guarantor Sub	Eliminations	Consolidated
ACTIVITIES Net income (loss) Adjustments to reconcile net loss to net cash flows	\$ (3,631,078)	\$ 4,790,978	\$ 6,024,819	\$ (10,815,797)	\$ (3,631,078)
from operating activities: (Equity) of subsidiaries Gain on life settlements Amortization of deferred	(4,791,035) —	(6,024,762)	— (14,516,881)	10,815,797 —	— (14,516,881)
financing and issuance costs Deferred income taxes Convertible, redeemable preferred stock dividends	1,103,312 (1,916,686)	49,339 —	781,125 —	_	1,933,776 (1,916,686)
payable (Increase) decrease in operating assets:	173,993	_	_	_	173,993
Policy benefits receivable Other assets Increase (decrease) in operating liabilities: Accounts payable and other	(22,146,946)	— (15,631,849)	2,142,986	37,360,805	2,142,986 (417,990)
accrued expenses NET CASH FLOWS USED IN OPERATING	2,010,129	(105,418)	629,558	_	2,534,269
ACTIVITIES	(29,198,311)	(16,921,712)	(4,938,393)	37,360,805	(13,697,611)
CASH FLOWS FROM INVESTING ACTIVITIES Investment in life					
settlements	_	_	(13,626,842)	_	(13,626,842)
Carrying value of matured life insurance contracts NET CASH FLOWS USED IN INVESTING	_	_	80,000	_	80,000
ACTIVITIES	_	_	(13,546,842)	_	(13,546,842)
CASH FLOWS FROM					

ACTIVITIES

110111111111111111111111111111111111111					
Payments for redemption of					
Series I Secured Notes	_	(890,586)		_	(890,586)
Proceeds from issuance of					
L Bonds	37,122,127	_		_	37,122,127
Payments for redemption					
and issuance of L Bonds	(19,363,047)	_		_	(19,363,047)
Proceeds (payments) from					
restricted cash	_	(2,203,800)	2,855,430	_	651,630
Issuance of member capital	_	21,730,944	15,629,861	(37,360,805)	_
Payments for redemption					
preferred stock	(21,187)	_	_	_	(21,187)
NET CASH FLOWS					
PROVIDED BY					
FINANCING ACTIVITIES	17,737,893	18,636,558	18,485,291	(37,360,805)	17,498,937
NET INCREASE					
(DECREASE) IN CASH					
AND CASH					
EQUIVALENTS	(11,460,418)	1,714,846	56	_	(9,745,516)
CASH AND CASH					
EQUIVALENTS					
BEGINNING OF THE					
PERIOD	37,814,528	233,553	150,108	_	38,198,189
END OF THE PERIOD	\$ 26,354,110	\$ 1,948,399	\$ 150,164	\$ —	\$ 28,452,673
F-28					

GWG HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

(19) Concentrations

We purchase life insurance contracts written by life insurance companies having investment grade ratings by independent rating agencies. As a result, there may be concentrations of contracts with certain life insurance companies. The following summarizes the face value of insurance contracts with specific life insurance companies exceeding 10% of the total face value held by us.

	September 30,			December 31,	
Life insurance company	2016		2015		
AXA Equitable	14.3	%	14.0	%	
John Hancock	13.0	%	12.7	%	
Lincoln National	11.5	%		*	
Transamerica	10.1	%		*	

^{*} percentage does not exceed 10% of the total face value.

The following summarizes the number of insurance contracts insuring the lives of persons living in specific states exceeding 10% of the total face value held by us:

	Septembe	September 30,		
State of Residence	2016		2015	
California	21.1	%	25.2	%
Florida	19.0	%	20.0	%
(20) Subsequent events				

Subsequent to September 30, 2016, two policies covering two individual matured. The life insurance contract benefits of these policies were \$3,240,000 and we recorded realized gains of \$2,539,000 on these policies.

Subsequent to September 30, 2016, we have issued approximately \$6,911,000 in additional principal amount of L Bonds, and 7,350 shares of RPS for gross consideration of approximately \$7,350,000.

On October 28, 2016, DLP IV completed the closing of the second of two initial advances contemplated under a Loan and Security Agreement with LNV. At this closing, a total of \$92,900,000 in loan proceeds were obtained by DLP IV, of which approximately \$16,250,000 was used to fund a reserve account required under the Loan and Security Agreement.

1,000,000 Units	
(\$1,000,000,000)	
GWG HOLDINGS, INC.	
L Bonds	
PROSPECTUS SUPPLEMENT	
	November 10, 2016